Trial Outcomes & Findings for Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) (NCT NCT00975130)

Last Updated: 2017-04-13

Results Overview

EULAR response was assessed at the end of Month 6 by the Disease Activity Score using the 28 tender and swollen joint count calculated with erythrocyte sedimentation rate values (DAS28-ESR). A good response was defined as a decrease \>1.2 units and a final DAS28-ESR \< 3.2 units, while a moderate response was defined as a decrease \> 1.2 units and final DAS28-ESR \>= 3.2 units, OR a decrease of 0.6 to 1.2 units AND final DAS28-ESR \<= 5.1 units

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

3366 participants

Primary outcome timeframe

Month 6

Results posted on

2017-04-13

Participant Flow

Participant milestones

Participant milestones
Measure	Golimumab 50 mg Subcutaneous (GLM50-SC) Participants received GLM50-SC once monthly for a period of 6 months in Study Part 1.	Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg Participants achieving good or moderate response but not in remission at the conclusion of Study Part 1 received IV-GLM at a dose of 2 mg/kg at the start of Month 7, start of Month 8, and start of Month 10 if remission was not achieved at any of these IV administration visits. If remission was achieved, participants were switched subcutaneous golimumab at a dose of 50 mg once monthly.	SC-GLM50 Participants achieving good or moderate response but not in remission at the end of Study Part 1, received subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months in Part 2 of the study.
Study Part 1 STARTED	3366	0	0
Study Part 1 COMPLETED	3086	0	0
Study Part 1 NOT COMPLETED	280	0	0
Study Part 2 STARTED	0	250	255
Study Part 2 COMPLETED	0	212	238
Study Part 2 NOT COMPLETED	0	38	17

Reasons for withdrawal

Reasons for withdrawal
Measure	Golimumab 50 mg Subcutaneous (GLM50-SC) Participants received GLM50-SC once monthly for a period of 6 months in Study Part 1.	Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg Participants achieving good or moderate response but not in remission at the conclusion of Study Part 1 received IV-GLM at a dose of 2 mg/kg at the start of Month 7, start of Month 8, and start of Month 10 if remission was not achieved at any of these IV administration visits. If remission was achieved, participants were switched subcutaneous golimumab at a dose of 50 mg once monthly.	SC-GLM50 Participants achieving good or moderate response but not in remission at the end of Study Part 1, received subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months in Part 2 of the study.
Study Part 1 Adverse Event	150	0	0
Study Part 1 Lost to Follow-up	19	0	0
Study Part 1 Withdrawal by Subject	61	0	0
Study Part 1 Protocol Violation	13	0	0
Study Part 1 Did Not Meet Protocol Eligibility	9	0	0
Study Part 1 Administrative	4	0	0
Study Part 1 Withdrew Consent	24	0	0
Study Part 2 Adverse Event	0	14	7
Study Part 2 Lost to Follow-up	0	0	1
Study Part 2 Withdrawal by Subject	0	13	5
Study Part 2 Withdrew Consent	0	6	2
Study Part 2 Did Not Meet Protocol Eligibility	0	4	1
Study Part 2 Administrative	0	1	0
Study Part 2 Protocol Violation	0	0	1

Baseline Characteristics

Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	GLM50-SC n=3280 Participants Participants received 50 mg of golimumab subcutaneously once monthly for a period of 6 months. 3280 enrolled participants were included in the Efficacy-Evaluable population; baseline characteristics are presented for this population.
Age, Continuous	53 Years n=5 Participants
Sex: Female, Male Female	2716 Participants n=5 Participants
Sex: Female, Male Male	564 Participants n=5 Participants

PRIMARY outcome

Timeframe: Month 6

Population: The Efficacy Evaluable population in Part 1 of the study excluded participants without a DAS28-ESR at baseline and at least 1 post-line value DAS28-ESR or those that had very poor data quality due to incomplete documentation.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Number of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6	2692 Participants	—

PRIMARY outcome

Timeframe: Start of Month 11, End of Month 12

Population: The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.

The number of participants experiencing DAS28-ESR remission was evaluated at the start of study Month 11 and the end of study Month 12. The DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR \<2.6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=242 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 n=248 Participants Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Number of Participants Experiencing Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at the Start of Month 11 and End of Month 12 Start of Month 11	58 Participants	64 Participants
Number of Participants Experiencing Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at the Start of Month 11 and End of Month 12 End of Month 12	59 Participants	67 Participants

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the mean number of swollen joints was calculated at study Month 2, Month 4, and Month 6 by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week). A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1995)	-6.2 Swollen Joints Standard Deviation 5.07	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1995)	-6.9 Swollen Joints Standard Deviation 5.30	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n =142)	-4.7 Swollen Joints Standard Deviation 4.46	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=142)	-6.3 Swollen Joints Standard Deviation 5.37	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=142)	-7.7 Swollen Joints Standard Deviation 5.59	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=526)	-4.6 Swollen Joints Standard Deviation 4.45	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=526)	-6.2 Swollen Joints Standard Deviation 4.98	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=526)	-7.1 Swollen Joints Standard Deviation 5.37	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Methotrexate (MTX) Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1995)	-4.5 Swollen Joints Standard Deviation 4.67	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of swollen joints was calculated by participant baseline background DMARD treatment regimen at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=216)	-4.6 Swollen Joints Standard Deviation 4.68	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=216)	-6.0 Swollen Joints Standard Deviation 5.11	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1681)	-4.5 Swollen Joints Standard Deviation 4.61	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1681)	-6.1 Swollen Joints Standard Deviation 5.07	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1681)	-6.9 Swollen Joints Standard Deviation 5.31	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=433)	-4.5 Swollen Joints Standard Deviation 4.91	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=433)	-6.5 Swollen Joints Standard Deviation 5.17	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=433)	-7.3 Swollen Joints Standard Deviation 5.35	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=216)	-6.7 Swollen Joints Standard Deviation 5.54	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=150)	-3.8 Swollen Joints Standard Deviation 4.58	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=150)	-5.9 Swollen Joints Standard Deviation 5.40	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=150)	-6.7 Swollen Joints Standard Deviation 6.10	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=106)	-4.8 Swollen Joints Standard Deviation 3.89	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=106)	-6.0 Swollen Joints Standard Deviation 4.96	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=106)	-6.2 Swollen Joints Standard Deviation 4.86	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=303)	-3.9 Swollen Joints Standard Deviation 4.27	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=303)	-5.6 Swollen Joints Standard Deviation 4.51	—
Mean Change From Baseline in the Number of Swollen Joints by Disease Modifying Antirheumatic Drug (DMARD) Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=303)	-6.2 Swollen Joints Standard Deviation 4.90	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of swollen joints by participant baseline concomitant corticosteroid treatment was calculated at study Month 2, Month 4, and Month 6 . A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1202)	-4.5 Swollen Joints Standard Deviation 4.43	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1202)	-6.1 Swollen Joints Standard Deviation 4.88	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1202)	-6.8 Swollen Joints Standard Deviation 5.24	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2078)	-4.3 Swollen Joints Standard Deviation 4.66	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2078)	-6.1 Swollen Joints Standard Deviation 5.10	—
Mean Change From Baseline in the Number of Swollen Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2078)	-6.9 Swollen Joints Standard Deviation 5.33	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the mean number of swollen joints by the number of baseline participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1129)	-4.7 Swollen Joints Standard Deviation 4.81	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1129)	-6.3 Swollen Joints Standard Deviation 5.35	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1129)	-7.2 Swollen Joints Standard Deviation 5.50	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1176)	-4.4 Swollen Joints Standard Deviation 4.54	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1176)	-6.0 Swollen Joints Standard Deviation 4.84	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1176)	-6.7 Swollen Joints Standard Deviation 5.24	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=974)	-4.1 Swollen Joints Standard Deviation 4.34	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=974)	-5.8 Swollen Joints Standard Deviation 4.83	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=974)	-6.6 Swollen Joints Standard Deviation 5.10	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the mean number of swollen joints was calculated by the participant duration of disease at study Month 2, Month 4, and Month 6. The participant duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=764)	-4.3 Swollen Joints Standard Deviation 4.63	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=899)	-4.4 Swollen Joints Standard Deviation 4.74	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n= 899)	-5.9 Swollen Joints Standard Deviation 5.08	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=899)	-6.5 Swollen Joints Standard Deviation 5.26	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=764)	-6.0 Swollen Joints Standard Deviation 5.04	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=764)	-6.8 Swollen Joints Standard Deviation 5.41	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=692)	-4.3 Swollen Joints Standard Deviation 4.49	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=692)	-6.1 Swollen Joints Standard Deviation 4.96	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=692)	-6.7 Swollen Joints Standard Deviation 5.40	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=924)	-4.6 Swollen Joints Standard Deviation 4.45	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=924)	-6.2 Swollen Joints Standard Deviation 4.99	—
Mean Change From Baseline in the Number of Swollen Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=924)	-7.2 Swollen Joints Standard Deviation 5.13	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of swollen joints by participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6 by the participant's level of baseline disease activity, as measured by DAS28-ESR. A total of 28 joints were evaluated. DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 to \< =5.1 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=698)	-2.4 Swollen Joints Standard Deviation 3.33	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=698)	-3.4 Swollen Joints Standard Deviation 3.43	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=698)	-3.8 Swollen Joints Standard Deviation 3.60	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2572)	-4.9 Swollen Joints Standard Deviation 4.73	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2572)	-6.8 Swollen Joints Standard Deviation 5.13	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2572)	-7.7 Swollen Joints Standard Deviation 5.39	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The change from baseline in the mean number of swollen joints was calculated by the participant baseline level of RF at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1026)	-3.9 Swollen Joints Standard Deviation 4.36	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1026)	-5.5 Swollen Joints Standard Deviation 4.85	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1026)	-6.2 Swollen Joints Standard Deviation 5.07	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1081)	-4.2 Swollen Joints Standard Deviation 4.47	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1081)	-5.8 Swollen Joints Standard Deviation 4.89	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1081)	-6.4 Swollen Joints Standard Deviation 5.08	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1127)	-5.0 Swollen Joints Standard Deviation 4.83	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1127)	-6.8 Swollen Joints Standard Deviation 5.25	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Rheumatoid Factor (RF) Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1127)	-7.8 Swollen Joints Standard Deviation 5.56	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The change from baseline in the mean number of swollen joints was calculated by the participant baseline level of anti-CCP at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1038)	-5.7 Swollen Joints Standard Deviation 4.89	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1038)	-6.5 Swollen Joints Standard Deviation 5.16	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1038)	-4.0 Swollen Joints Standard Deviation 4.44	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1112)	-4.4 Swollen Joints Standard Deviation 4.41	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1112)	-6.1 Swollen Joints Standard Deviation 4.92	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1112)	-6.7 Swollen Joints Standard Deviation 5.23	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1075)	-4.8 Swollen Joints Standard Deviation 4.86	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1075)	-6.3 Swollen Joints Standard Deviation 5.30	—
Mean Change From Baseline in the Number of Swollen Joints by Baseline Anti-Cyclic Citrullinated Antibody (Anti-CCP) Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1075)	-7.3 Swollen Joints Standard Deviation 5.51	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The change from baseline in the mean number of swollen joints was calculated by the baseline participant smoking status at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1963)	-4.7 Swollen Joints Standard Deviation 4.66	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1963)	-6.5 Swollen Joints Standard Deviation 5.05	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1963)	-7.3 Swollen Joints Standard Deviation 5.35	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=324)	-4.4 Swollen Joints Standard Deviation 4.43	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=324)	-5.5 Swollen Joints Standard Deviation 5.22	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=324)	-6.5 Swollen Joints Standard Deviation 5.35	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=314)	-4.0 Swollen Joints Standard Deviation 4.32	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=314)	-5.4 Swollen Joints Standard Deviation 4.64	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=314)	-6.1 Swollen Joints Standard Deviation 4.85	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=223)	-4.0 Swollen Joints Standard Deviation 4.71	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=223)	-6.1 Swollen Joints Standard Deviation 4.87	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=223)	-6.6 Swollen Joints Standard Deviation 5.26	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=397)	-3.6 Swollen Joints Standard Deviation 4.11	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=397)	-5.0 Swollen Joints Standard Deviation 4.59	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=397)	-5.5 Swollen Joints Standard Deviation 4.95	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=59)	-4.0 Swollen Joints Standard Deviation 5.6	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=59)	-4.8 Swollen Joints Standard Deviation 6.25	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=59)	-5.0 Swollen Joints Standard Deviation 5.46	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=423)	-4.2 Swollen Joints Standard Deviation 4.68	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=423)	-6.0 Swollen Joints Standard Deviation 5.04	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=423)	-6.5 Swollen Joints Standard Deviation 5.21	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=454)	-3.8 Swollen Joints Standard Deviation 4.12	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=454)	-5.3 Swollen Joints Standard Deviation 4.84	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=454)	-5.9 Swollen Joints Standard Deviation 5.17	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=418)	-3.9 Swollen Joints Standard Deviation 4.35	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=418)	-5.0 Swollen Joints Standard Deviation 4.77	—
Mean Change From Baseline in the Number of Swollen Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=418)	-5.8 Swollen Joints Standard Deviation 5.01	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The change from baseline in the mean number of swollen joints was calculated by the baseline participant eligibility for anti-TNF treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=106)	-3.1 Swollen Joints Standard Deviation 3.34	—
Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=106)	-4.4 Swollen Joints Standard Deviation 3.82	—
Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=106)	-4.5 Swollen Joints Standard Deviation 3.81	—
Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3174)	-4.4 Swollen Joints Standard Deviation 4.61	—
Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3174)	-6.1 Swollen Joints Standard Deviation 5.05	—
Mean Change From Baseline in the Number of Swollen Joints by Eligibility for Anti-Tumor Necrosis Factor (Anti-TNF) Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3174)	-6.9 Swollen Joints Standard Deviation 5.32	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

Population: The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline. Participants were grouped by participant expectation score into 3 groups: \<=1.5, \>1.5 to \<1.86, and \>=1.86.

The mean change from baseline in the number of swollen joints was calculated by the participant baseline expectation of treatment outcome at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1212)	-4.8 Swollen Joints Standard Deviation 4.68	—
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1212)	-6.4 Swollen Joints Standard Deviation 5.14	—
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1212)	-7.3 Swollen Joints Standard Deviation 5.40	—
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=1009)	-4.4 Swollen Joints Standard Deviation 4.54	—
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=1009)	-6.2 Swollen Joints Standard Deviation 5.09	—
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=1009)	-6.9 Swollen Joints Standard Deviation 5.28	—
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1054)	-3.9 Swollen Joints Standard Deviation 4.46	—
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1054)	-5.5 Swollen Joints Standard Deviation 4.77	—
Mean Change From Baseline in the Number of Swollen Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1054)	-6.3 Swollen Joints Standard Deviation 5.13	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of swollen joints was calculated by the physician experience level at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1305)	-4.2 Swollen Joints Standard Deviation 4.49	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1305)	-5.8 Swollen Joints Standard Deviation 4.88	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n =1305)	-6.5 Swollen Joints Standard Deviation 5.13	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1105)	-4.7 Swollen Joints Standard Deviation 4.83	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1105)	-6.4 Swollen Joints Standard Deviation 5.35	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1105)	-7.2 Swollen Joints Standard Deviation 5.42	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=850)	-4.3 Swollen Joints Standard Deviation 4.35	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=850)	-6.0 Swollen Joints Standard Deviation 4.77	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=850)	-6.8 Swollen Joints Standard Deviation 5.32	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of swollen joints was calculated by the physician experience level with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1160)	-4.2 Swollen Joints Standard Deviation 4.52	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1160)	-5.9 Swollen Joints Standard Deviation 5.09	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1160)	-6.9 Swollen Joints Standard Deviation 5.35	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1745)	-4.5 Swollen Joints Standard Deviation 4.63	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1745)	-6.2 Swollen Joints Standard Deviation 4.98	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1745)	-6.8 Swollen Joints Standard Deviation 5.26	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=355)	-4.3 Swollen Joints Standard Deviation 4.49	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=355)	-5.9 Swollen Joints Standard Deviation 4.98	—
Mean Change From Baseline in the Number of Swollen Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=355)	-6.6 Swollen Joints Standard Deviation 5.18	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of swollen joints was calculated by the baseline number of patients the physician treats with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The number of patients treated with biologics is defined as the number of patients treated by the physician in the last month with biologics for rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1056)	-4.3 Swollen Joints Standard Deviation 4.59	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1056)	-6.2 Swollen Joints Standard Deviation 5.00	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1056)	-7.4 Swollen Joints Standard Deviation 5.40	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1061)	-4.5 Swollen Joints Standard Deviation 4.52	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1061)	-6.1 Swollen Joints Standard Deviation 4.98	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1061)	-6.8 Swollen Joints Standard Deviation 5.02	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1097)	-4.5 Swollen Joints Standard Deviation 4.60	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1097)	-6.1 Swollen Joints Standard Deviation 4.98	—
Mean Change From Baseline in the Number of Swollen Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1097)	-6.8 Swollen Joints Standard Deviation 5.02	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of swollen joints was calculated by the physician's expectation of treatment outcome at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The physician's expectation of treatment outcomes was assessed at the start of Month 4 at which time physicians were asked to rate their expectations of treatment outcome in each participant as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=40)	-5.5 Swollen Joints Standard Deviation 4.74	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=40)	-7.1 Swollen Joints Standard Deviation 4.21	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=40)	-8.2 Swollen Joints Standard Deviation 4.77	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=325)	-4.9 Swollen Joints Standard Deviation 4.98	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=325)	-6.3 Swollen Joints Standard Deviation 4.94	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=325)	-7.2 Swollen Joints Standard Deviation 5.75	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1932)	-4.2 Swollen Joints Standard Deviation 4.53	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1932)	-6.0 Swollen Joints Standard Deviation 5.12	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1932)	-6.9 Swollen Joints Standard Deviation 5.23	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=966)	-4.6 Swollen Joints Standard Deviation 4.50	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=966)	-6.0 Swollen Joints Standard Deviation 4.84	—
Mean Change From Baseline in the Number of Swollen Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=966)	-6.5 Swollen Joints Standard Deviation 5.24	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by participant concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=142)	-7.9 Tender Joints Standard Deviation 6.67	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=142)	-5.5 Tender Joints Standard Deviation 5.82	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=142)	-9.0 Tender Joints Standard Deviation 6.82	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=526)	-5.6 Tender Joints Standard Deviation 5.76	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=526)	-8.0 Tender Joints Standard Deviation 6.52	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=526)	-9.1 Tender Joints Standard Deviation 6.57	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1995)	-5.5 Tender Joints Standard Deviation 5.91	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1995)	-7.8 Tender Joints Standard Deviation 6.48	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1995)	-8.7 Tender Joints Standard Deviation 6.72	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by participant background DMARD treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1681)	-5.5 Tender Joints Standard Deviation 5.56	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1681)	-7.8 Tender Joints Standard Deviation 6.39	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1681)	-8.7 Tender Joints Standard Deviation 6.58	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=433)	-5.7 Tender Joints Standard Deviation 6.37	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=433)	-8.0 Tender Joints Standard Deviation 6.81	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=433)	-9.2 Tender Joints Standard Deviation 6.46	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=216)	-5.6 Tender Joints Standard Deviation 6.86	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=216)	-7.6 Tender Joints Standard Deviation 6.87	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=216)	-8.2 Tender Joints Standard Deviation 7.52	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=150)	-5.5 Tender Joints Standard Deviation 6.11	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=150)	-8.0 Tender Joints Standard Deviation 6.92	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=150)	-9.2 Tender Joints Standard Deviation 7.44	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=106)	-5.4 Tender Joints Standard Deviation 5.72	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=106)	-8.3 Tender Joints Standard Deviation 5.81	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=106)	-8.4 Tender Joints Standard Deviation 7.07	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=303)	-5.1 Tender Joints Standard Deviation 5.77	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=303)	-7.5 Tender Joints Standard Deviation 6.37	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=303)	-8.0 Tender Joints Standard Deviation 6.68	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by participant baseline concomitant steroid treatment at study Month 2, Month 4, and Month 6. A total 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1202)	-5.4 Tender Joints Standard Deviation 5.54	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1202)	-7.6 Tender Joints Standard Deviation 6.31	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1202)	-8.6 Tender Joints Standard Deviation 6.44	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2078)	-5.6 Tender Joints Standard Deviation 5.99	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2078)	-7.8 Tender Joints Standard Deviation 6.61	—
Mean Change From Baseline in the Number of Tender Joints by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2078)	-8.7 Tender Joints Standard Deviation 6.85	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the number of participant DMARD failures at baseline at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1176)	-5.5 Tender Joints Standard Deviation 6.02	—
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1176)	-7.7 Tender Joints Standard Deviation 6.64	—
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1176)	-8.7 Tender Joints Standard Deviation 6.64	—
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=974)	-5.1 Tender Joints Standard Deviation 5.68	—
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=974)	-7.6 Tender Joints Standard Deviation 6.15	—
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=974)	-8.4 Tender Joints Standard Deviation 6.48	—
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1129)	-5.8 Tender Joints Standard Deviation 5.74	—
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1129)	-7.8 Tender Joints Standard Deviation 6.65	—
Mean Change From Baseline in the Number of Tender Joints by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1129)	-8.8 Tender Joints Standard Deviation 6.94	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the participant duration of disease at study Month 2, Month 4, and Month 6. Duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=899)	-5.4 Tender Joints Standard Deviation 6.03	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=899)	-7.4 Tender Joints Standard Deviation 6.78	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=899)	-8.3 Tender Joints Standard Deviation 6.59	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=764)	-5.9 Tender Joints Standard Deviation 5.95	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=764)	-8.2 Tender Joints Standard Deviation 6.43	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=764)	-8.9 Tender Joints Standard Deviation 6.86	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=692)	-5.3 Tender Joints Standard Deviation 5.52	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=692)	-7.7 Tender Joints Standard Deviation 6.27	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=692)	-8.6 Tender Joints Standard Deviation 6.66	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=924)	-5.4 Tender Joints Standard Deviation 5.74	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=924)	-7.6 Tender Joints Standard Deviation 6.45	—
Mean Change From Baseline in the Number of Tender Joints by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=924)	-8.7 Tender Joints Standard Deviation 6.67	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the participant baseline level of disease activity, as measured by DAS28, at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 to \< =5.1 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=698)	-2.9 Tender Joints Standard Deviation 4.10	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=698)	-3.8 Tender Joints Standard Deviation 4.42	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=698)	-4.0 Tender Joints Standard Deviation 4.59	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2572)	-6.2 Tender Joints Standard Deviation 6.00	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2572)	-8.8 Tender Joints Standard Deviation 6.55	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2572)	-9.9 Tender Joints Standard Deviation 6.62	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The change from baseline in the mean number of tender joints was calculated by the participant baseline level of RF at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1026)	-5.0 Tender Joints Standard Deviation 5.82	—
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1026)	-7.2 Tender Joints Standard Deviation 6.60	—
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1026)	-8.1 Tender Joints Standard Deviation 6.76	—
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1081)	-5.4 Tender Joints Standard Deviation 5.46	—
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1081)	-7.6 Tender Joints Standard Deviation 6.20	—
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1081)	-8.5 Tender Joints Standard Deviation 6.36	—
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1127)	-6.1 Tender Joints Standard Deviation 6.16	—
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1127)	-8.3 Tender Joints Standard Deviation 6.69	—
Mean Change From Baseline in the Number of Tender Joints by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1127)	-9.3 Tender Joints Standard Deviation 6.97	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the participant baseline level of anti-CCP at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1038)	-5.0 Tender Joints Standard Deviation 5.78	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1038)	-7.2 Tender Joints Standard Deviation 6.64	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1038)	-8.1 Tender Joints Standard Deviation 6.73	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1112)	-5.7 Tender Joints Standard Deviation 5.73	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1112)	-8.0 Tender Joints Standard Deviation 6.39	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1112)	-8.8 Tender Joints Standard Deviation 6.72	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1075)	-5.8 Tender Joints Standard Deviation 5.95	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1075)	-7.9 Tender Joints Standard Deviation 6.49	—
Mean Change From Baseline in the Number of Tender Joints by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1075)	-9.0 Tender Joints Standard Deviation 6.65	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the baseline participant smoking status at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=324)	-5.5 Tender Joints Standard Deviation 5.97	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=324)	-7.4 Tender Joints Standard Deviation 6.73	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1963)	-5.8 Tender Joints Standard Deviation 5.86	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1963)	-8.2 Tender Joints Standard Deviation 6.49	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1963)	-9.2 Tender Joints Standard Deviation 6.59	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=324)	-8.7 Tender Joints Standard Deviation 6.77	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=314)	-5.7 Tender Joints Standard Deviation 5.74	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=314)	-7.5 Tender Joints Standard Deviation 6.12	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=314)	-8.4 Tender Joints Standard Deviation 6.51	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=223)	-4.6 Tender Joints Standard Deviation 5.11	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=223)	-7.2 Tender Joints Standard Deviation 6.67	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=223)	-8.2 Tender Joints Standard Deviation 6.84	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=397)	-4.4 Tender Joints Standard Deviation 5.67	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=397)	-6.4 Tender Joints Standard Deviation 6.36	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=397)	-6.7 Tender Joints Standard Deviation 6.70	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=59)	-5.2 Tender Joints Standard Deviation 6.83	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=59)	-6.9 Tender Joints Standard Deviation 6.49	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=59)	-7.5 Tender Joints Standard Deviation 7.64	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=423)	-5.4 Tender Joints Standard Deviation 5.51	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=423)	-7.5 Tender Joints Standard Deviation 6.37	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=423)	-8.4 Tender Joints Standard Deviation 6.77	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=454)	-5.2 Tender Joints Standard Deviation 5.67	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=454)	-7.6 Tender Joints Standard Deviation 6.37	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=454)	-8.1 Tender Joints Standard Deviation 6.80	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=418)	-4.5 Tender Joints Standard Deviation 5.76	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=418)	-6.1 Tender Joints Standard Deviation 6.29	—
Mean Change From Baseline in the Number of Tender Joints by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=418)	-7.1 Tender Joints Standard Deviation 6.61	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the baseline participant eligibility for anti-TNF treatment at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=106)	-4.6 Tender Joints Standard Deviation 4.75	—
Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=106)	-7.0 Tender Joints Standard Deviation 5.68	—
Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=106)	-7.0 Tender Joints Standard Deviation 5.70	—
Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3174)	-5.5 Tender Joints Standard Deviation 5.86	—
Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3174)	-7.7 Tender Joints Standard Deviation 6.53	—
Mean Change From Baseline in the Number of Tender Joints by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3174)	-8.7 Tender Joints Standard Deviation 6.72	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the participant baseline expectation of treatment outcome at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1212)	-6.1 Tender Joints Standard Deviation 5.97	—
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1212)	-8.2 Tender Joints Standard Deviation 6.40	—
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1212)	-9.2 Tender Joints Standard Deviation 6.69	—
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=1009)	-5.5 Tender Joints Standard Deviation 5.73	—
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=1009)	-7.9 Tender Joints Standard Deviation 6.67	—
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=1009)	-8.8 Tender Joints Standard Deviation 6.77	—
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1054)	-4.8 Tender Joints Standard Deviation 5.67	—
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1054)	-6.9 Tender Joints Standard Deviation 6.39	—
Mean Change From Baseline in the Number of Tender Joints by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1054)	-7.8 Tender Joints Standard Deviation 6.58	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the physician experience level at study Month 2, Month 4, Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1305)	-5.3 Tender Joints Standard Deviation 5.80	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1305)	-7.9 Tender Joints Standard Deviation 6.41	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1305)	-8.7 Tender Joints Standard Deviation 6.58	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1105)	-5.6 Tender Joints Standard Deviation 5.80	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1105)	-7.7 Tender Joints Standard Deviation 6.48	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1105)	-8.8 Tender Joints Standard Deviation 6.59	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=850)	-5.5 Tender Joints Standard Deviation 5.89	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=850)	-7.6 Tender Joints Standard Deviation 6.69	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=850)	-8.4 Tender Joints Standard Deviation 7.01	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the physician experience level with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1160)	-8.9 Tender Joints Standard Deviation 6.76	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1745)	-5.5 Tender Joints Standard Deviation 5.78	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1160)	-5.5 Tender Joints Standard Deviation 5.93	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1160)	-8.0 Tender Joints Standard Deviation 6.54	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1745)	-7.6 Tender Joints Standard Deviation 6.51	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1745)	-8.6 Tender Joints Standard Deviation 6.61	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=355)	-5.3 Tender Joints Standard Deviation 5.66	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=355)	-7.4 Tender Joints Standard Deviation 6.34	—
Mean Change From Baseline in the Number of Tender Joints by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=355)	-8.0 Tender Joints Standard Deviation 6.90	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints was calculated by the baseline number of patients the physician treats with biologics at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The number of patients treated with biologics is defined as the number of patients treated by the physician in the last month with biologics for rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1056)	-5.5 Tender Joints Standard Deviation 5.95	—
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1056)	-8.0 Tender Joints Standard Deviation 6.33	—
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1056)	-9.2 Tender Joints Standard Deviation 6.62	—
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1061)	-5.7 Tender Joints Standard Deviation 5.69	—
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1061)	-7.8 Tender Joints Standard Deviation 6.59	—
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1061)	-8.6 Tender Joints Standard Deviation 6.44	—
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1097)	-5.3 Tender Joints Standard Deviation 5.79	—
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1097)	-7.5 Tender Joints Standard Deviation 6.54	—
Mean Change From Baseline in the Number of Tender Joints by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1097)	-8.2 Tender Joints Standard Deviation 6.93	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the number of tender joints. was calculated by the physician's expectation of treatment outcome at study Month 2, Month 4, and Month 6. A total of 28 joints were evaluated. The physician's expectation of treatment outcomes was assessed at the start of Month 4 at which time physicians were asked to rate their expectations of treatment outcome in each participant as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=40)	-7.2 Tender Joints Standard Deviation 5.80	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=40)	-9.4 Tender Joints Standard Deviation 6.32	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=40)	-10.4 Tender Joints Standard Deviation 6.32	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=325)	-5.0 Tender Joints Standard Deviation 6.02	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=325)	-7.3 Tender Joints Standard Deviation 6.83	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=325)	-8.3 Tender Joints Standard Deviation 6.82	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1932)	-5.5 Tender Joints Standard Deviation 5.86	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1932)	-7.9 Tender Joints Standard Deviation 6.58	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1932)	-8.9 Tender Joints Standard Deviation 6.85	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=966)	-5.6 Tender Joints Standard Deviation 5.68	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=966)	-7.5 Tender Joints Standard Deviation 6.22	—
Mean Change From Baseline in the Number of Tender Joints by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=966)	-8.3 Tender Joints Standard Deviation 6.32	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant global assessment of disease activity was calculated by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a visual analogue scale (VAS; 0mm \[best\] -100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=142)	-27.9 Score on a Scale Standard Deviation 29.33	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=526)	-22.6 Score on a Scale Standard Deviation 22.99	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=526)	-28.9 Score on a Scale Standard Deviation 24.93	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=526)	-32.4 Score on a Scale Standard Deviation 27.85	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=142)	-23.1 Score on a Scale Standard Deviation 24.89	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=142)	-29.3 Score on a Scale Standard Deviation 26.58	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1995)	-20.3 Score on a Scale Standard Deviation 25.07	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1995)	-26.2 Score on a Scale Standard Deviation 27.46	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1995)	-30.0 Score on a Scale Standard Deviation 28.68	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=433)	-19.2 Score on a Scale Standard Deviation 24.84	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1681)	-21.2 Score on a Scale Standard Deviation 24.61	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1681)	-27.5 Score on a Scale Standard Deviation 27.23	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1681)	-30.7 Score on a Scale Standard Deviation 28.48	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=433)	-26.4 Score on a Scale Standard Deviation 27.18	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=433)	-30.8 Score on a Scale Standard Deviation 29.14	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=216)	-19.8 Score on a Scale Standard Deviation 25.82	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=216)	-23.8 Score on a Scale Standard Deviation 28.38	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=216)	-26.4 Score on a Scale Standard Deviation 28.74	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=150)	-23.3 Score on a Scale Standard Deviation 25.13	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=150)	-27.2 Score on a Scale Standard Deviation 24.16	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=150)	-32.1 Score on a Scale Standard Deviation 28.95	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=106)	-21.1 Score on a Scale Standard Deviation 23.93	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=106)	-27.3 Score on a Scale Standard Deviation 24.14	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=106)	-28.9 Score on a Scale Standard Deviation 28.75	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=303)	-21.8 Score on a Scale Standard Deviation 24.95	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=303)	-26.5 Score on a Scale Standard Deviation 28.61	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=303)	-29.5 Score on a Scale Standard Deviation 29.29	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2078)	-21.3 Score on a Scale Standard Deviation 25.04	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2078)	-26.4 Score on a Scale Standard Deviation 27.33	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1202)	-20.5 Score on a Scale Standard Deviation 23.98	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1202)	-27.0 Score on a Scale Standard Deviation 26.90	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1202)	-29.2 Score on a Scale Standard Deviation 28.68	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2078)	-30.7 Score on a Scale Standard Deviation 28.42	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1176)	-30.1 Score on a Scale Standard Deviation 28.58	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1129)	-20.9 Score on a Scale Standard Deviation 23.98	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1129)	-27.1 Score on a Scale Standard Deviation 28.25	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1129)	-29.9 Score on a Scale Standard Deviation 29.42	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1176)	-20.8 Score on a Scale Standard Deviation 24.56	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1176)	-26.1 Score on a Scale Standard Deviation 26.67	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=974)	-21.3 Score on a Scale Standard Deviation 23.73	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=974)	-26.8 Score on a Scale Standard Deviation 26.52	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=974)	-30.4 Score on a Scale Standard Deviation 27.43	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=764)	-25.9 Score on a Scale Standard Deviation 27.38	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=764)	-28.9 Score on a Scale Standard Deviation 28.26	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=692)	-22.2 Score on a Scale Standard Deviation 24.76	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=924)	-31.8 Score on a Scale Standard Deviation 27.91	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=899)	-19.4 Score on a Scale Standard Deviation 25.51	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=899)	-25.6 Score on a Scale Standard Deviation 28.21	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=899)	-29.5 Score on a Scale Standard Deviation 29.45	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=764)	-20.9 Score on a Scale Standard Deviation 24.33	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=692)	-27.8 Score on a Scale Standard Deviation 26.51	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=692)	-30.2 Score on a Scale Standard Deviation 28.36	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=924)	-21.8 Score on a Scale Standard Deviation 23.96	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=924)	-27.3 Score on a Scale Standard Deviation 26.46	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=698)	-16.0 Score on a Scale Standard Deviation 23.68	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=698)	-20.0 Score on a Scale Standard Deviation 26.21	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=698)	-22.6 Score on a Scale Standard Deviation 27.31	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2572)	-22.4 Score on a Scale Standard Deviation 24.73	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2572)	-28.5 Score on a Scale Standard Deviation 27.15	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2572)	-32.3 Score on a Scale Standard Deviation 28.47	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1026)	18.0 Score on a Scale Standard Deviation 24.82	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1026)	-24.7 Score on a Scale Standard Deviation 27.89	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1026)	-27.6 Score on a Scale Standard Deviation 28.48	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1081)	-20.7 Score on a Scale Standard Deviation 24.07	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1081)	-25.7 Score on a Scale Standard Deviation 26.77	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1081)	-28.5 Score on a Scale Standard Deviation 28.15	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1127)	-24.2 Score on a Scale Standard Deviation 24.81	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1127)	-29.6 Score on a Scale Standard Deviation 26.72	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1127)	-34.2 Score on a Scale Standard Deviation 28.54	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1038)	-17.2 Score on a Scale Standard Deviation 24.22	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1112)	-28.1 Score on a Scale Standard Deviation 27.86	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1112)	-29.7 Score on a Scale Standard Deviation 28.88	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1075)	-23.1 Score on a Scale Standard Deviation 23.99	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1075)	-28.4 Score on a Scale Standard Deviation 26.44	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1038)	-23.3 Score on a Scale Standard Deviation 27.04	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1038)	-27.4 Score on a Scale Standard Deviation 28.21	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1112)	-22.6 Score on a Scale Standard Deviation 25.23	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1075)	-33.3 Score on a Scale Standard Deviation 28.26	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=454)	-28.4 Score on a Scale Standard Deviation 29.04	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=418)	-20.6 Score on a Scale Standard Deviation 25.00	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1963)	-20.7 Score on a Scale Standard Deviation 24.43	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1963)	-27.3 Score on a Scale Standard Deviation 26.73	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1963)	-31.5 Score on a Scale Standard Deviation 27.99	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=324)	-21.1 Score on a Scale Standard Deviation 25.34	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=324)	-26.2 Score on a Scale Standard Deviation 27.96	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=324)	-29.9 Score on a Scale Standard Deviation 28.05	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=314)	-24.2 Score on a Scale Standard Deviation 24.92	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=314)	-28.5 Score on a Scale Standard Deviation 27.04	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=314)	-31.2 Score on a Scale Standard Deviation 27.73	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=223)	-17.5 Score on a Scale Standard Deviation 23.82	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=223)	-24.0 Score on a Scale Standard Deviation 27.76	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=223)	-26.3 Score on a Scale Standard Deviation 29.99	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=397)	-21.3 Score on a Scale Standard Deviation 24.57	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=397)	-24.7 Score on a Scale Standard Deviation 27.65	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=397)	-26.3 Score on a Scale Standard Deviation 30.57	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=59)	-21.9 Score on a Scale Standard Deviation 29.42	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=59)	-20.7 Score on a Scale Standard Deviation 31.65	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=59)	-22.8 Score on a Scale Standard Deviation 29.35	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=423)	-21.9 Score on a Scale Standard Deviation 25.21	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=423)	-26.4 Score on a Scale Standard Deviation 27.80	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=423)	-29.8 Score on a Scale Standard Deviation 28.76	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=454)	-21.4 Score on a Scale Standard Deviation 24.97	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=454)	-27.3 Score on a Scale Standard Deviation 26.86	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=418)	-23.2 Score on a Scale Standard Deviation 28.82	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=418)	-26.3 Score on a Scale Standard Deviation 28.89	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=106)	-18.9 Score on a Scale Standard Deviation 21.65	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=106)	-24.7 Score on a Scale Standard Deviation 24.02	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=106)	-25.8 Score on a Scale Standard Deviation 27.59	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3174)	-21.0 Score on a Scale Standard Deviation 24.75	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3174)	-26.7 Score on a Scale Standard Deviation 27.27	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3174)	-30.3 Score on a Scale Standard Deviation 28.54	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1212)	-23.9 Score on a Scale Standard Deviation 25.79	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1212)	-29.5 Score on a Scale Standard Deviation 28.50	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1212)	-33.9 Score on a Scale Standard Deviation 28.65	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=1009)	-21.3 Score on a Scale Standard Deviation 24.59	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=1009)	-27.0 Score on a Scale Standard Deviation 27.03	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=1009)	-30.3 Score on a Scale Standard Deviation 28.79	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1054)	-17.3 Score on a Scale Standard Deviation 22.83	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1054)	-22.8 Score on a Scale Standard Deviation 25.20	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1054)	-25.6 Score on a Scale Standard Deviation 27.53	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1305)	-21.0 Score on a Scale Standard Deviation 24.66	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1305)	-26.2 Score on a Scale Standard Deviation 26.73	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1305)	-29.6 Score on a Scale Standard Deviation 28.41	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1105)	-20.8 Score on a Scale Standard Deviation 24.01	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1105)	-27.5 Score on a Scale Standard Deviation 26.88	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1105)	-31.1 Score on a Scale Standard Deviation 28.37	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=850)	-21.3 Score on a Scale Standard Deviation 25.30	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=850)	-26.2 Score on a Scale Standard Deviation 28.21	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=850)	-29.8 Score on a Scale Standard Deviation 28.72	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1160)	-21.2 Score on a Scale Standard Deviation 24.02	—
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1160)	-26.8 Score on a Scale Standard Deviation 25.74	—
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1160)	-30.4 Score on a Scale Standard Deviation 27.68	—
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1745)	-20.9 Score on a Scale Standard Deviation 24.99	—
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1745)	-26.5 Score on a Scale Standard Deviation 27.81	—
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1745)	-29.8 Score on a Scale Standard Deviation 29.06	—
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=355)	-20.5 Score on a Scale Standard Deviation 24.60	—
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=355)	-27.3 Score on a Scale Standard Deviation 28.62	—
mm [Best]Mean Change From Baseline in Participant Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=355)	-31.2 Score on a Scale Standard Deviation 28.22	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1056)	-21.0 Score on a Scale Standard Deviation 23.25	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1056)	-26.3 Score on a Scale Standard Deviation 25.27	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1056)	-31.4 Score on a Scale Standard Deviation 27.38	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1061)	-20.8 Score on a Scale Standard Deviation 24.98	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1061)	-26.7 Score on a Scale Standard Deviation 27.63	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1061)	-28.8 Score on a Scale Standard Deviation 28.63	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1097)	-21.2 Score on a Scale Standard Deviation 25.38	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1097)	-27.0 Score on a Scale Standard Deviation 28.19	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1097)	-30.3 Score on a Scale Standard Deviation 29.13	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant global assessment of disease activity by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=325)	-23.4 Score on a Scale Standard Deviation 27.22	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=325)	-28.3 Score on a Scale Standard Deviation 27.88	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=966)	-26.5 Score on a Scale Standard Deviation 27.25	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=40)	-25.1 Score on a Scale Standard Deviation 25.56	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=40)	-22.4 Score on a Scale Standard Deviation 24.52	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=40)	-30.6 Score on a Scale Standard Deviation 27.95	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=325)	-17.3 Score on a Scale Standard Deviation 24.53	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1932)	-21.4 Score on a Scale Standard Deviation 24.36	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1932)	-27.3 Score on a Scale Standard Deviation 27.08	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1932)	-31.0 Score on a Scale Standard Deviation 28.16	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=966)	-21.2 Score on a Scale Standard Deviation 25.13	—
Mean Change From Baseline in Participant Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=966)	-28.9 Score on a Scale Standard Deviation 29.27	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The change from baseline in participant serum ESR was calculated by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1995)	-9.2 mm/h Standard Deviation 17.85	—
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1995)	-10.3 mm/h Standard Deviation 19.03	—
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1995)	-10.9 mm/h Standard Deviation 20.43	—
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=142)	-9.4 mm/h Standard Deviation 14.73	—
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=142)	-9.8 mm/h Standard Deviation 18.98	—
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=142)	-9.2 mm/h Standard Deviation 21.99	—
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=526)	-11.2 mm/h Standard Deviation 17.91	—
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=526)	-11.5 mm/h Standard Deviation 21.29	—
Mean Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=526)	-12.8 mm/h Standard Deviation 22.52	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by concomitant DMARD background treatment was calculated at study Month 2, Month 4, and Month 6. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1681)	-9.8 mm/h Standard Deviation 17.03	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=433)	-9.2 mm/h Standard Deviation 20.60	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=433)	-10.9 mm/h Standard Deviation 22.12	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=216)	-10.0 mm/h Standard Deviation 20.15	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=216)	-9.9 mm/h Standard Deviation 19.25	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=216)	-9.8 mm/h Standard Deviation 22.15	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=150)	-10.3 mm/h Standard Deviation 15.74	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=150)	-14.9 mm/h Standard Deviation 23.30	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=150)	-11.9 mm/h Standard Deviation 21.73	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=106)	-10.0 mm/h Standard Deviation 18.88	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=106)	-8.7 mm/h Standard Deviation 19.13	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=106)	-9.0 mm/h Standard Deviation 20.65	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=303)	-7.6 mm/h Standard Deviation 17.87	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=303)	-8.1 mm/h Standard Deviation 20.40	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=303)	-8.3 mm/h Standard Deviation 21.40	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1681)	-10.9 mm/h Standard Deviation 18.94	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1681)	-11.6 mm/h Standard Deviation 20.53	—
Mean Change From Baseline in ESR by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=433)	-8.1 mm/h Standard Deviation 19.27	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in serum ESR by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1202)	-9.3 mm/h Standard Deviation 16.83	—
Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1202)	-10.4 mm/h Standard Deviation 18.58	—
Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1202)	-10.7 mm/h Standard Deviation 20.59	—
Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2078)	-9.4 mm/h Standard Deviation 18.28	—
Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2078)	-10.1 mm/h Standard Deviation 20.02	—
Mean Change From Baseline in ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2078)	-10.7 mm/h Standard Deviation 21.36	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1129)	-10.0 mm/h Standard Deviation 17.77	—
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1129)	-11.5 mm/h Standard Deviation 20.15	—
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1129)	-12.0 mm/h Standard Deviation 21.71	—
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1176)	-9.0 mm/h Standard Deviation 18.03	—
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1176)	-9.6 mm/h Standard Deviation 19.25	—
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1176)	-10.3 mm/h Standard Deviation 20.83	—
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=974)	-9.1 mm/h Standard Deviation 17.42	—
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=974)	-9.5 mm/h Standard Deviation 18.96	—
Mean Change From Baseline in ESR by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=974)	-9.9 mm/h Standard Deviation 20.61	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant serum ESR by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=899)	-8.6 mm/h Standard Deviation 17.77	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=899)	-10.6 mm/h Standard Deviation 20.08	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=899)	-11.2 mm/h Standard Deviation 21.35	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=764)	-9.1 mm/h Standard Deviation 17.97	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=764)	-9.5 mm/h Standard Deviation 19.60	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=764)	-9.4 mm/h Standard Deviation 20.81	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=692)	-9.5 mm/h Standard Deviation 17.69	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=692)	-10.2 mm/h Standard Deviation 18.85	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=692)	-11.4 mm/h Standard Deviation 21.47	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=924)	-10.2 mm/h Standard Deviation 17.63	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=924)	-10.5 mm/h Standard Deviation 19.37	—
Mean Change From Baseline in ESR by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=924)	-10.9 mm/h Standard Deviation 20.74	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 to \< =5.1 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=698)	-3.3 mm/h Standard Deviation 11.24	—
Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=698)	-2.2 mm/h Standard Deviation 13.03	—
Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=698)	-2.2 mm/h Standard Deviation 13.83	—
Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2572)	-11.1 mm/h Standard Deviation 18.76	—
Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2572)	-12.4 mm/h Standard Deviation 20.36	—
Mean Change From Baseline in ESR by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2572)	-13.1 mm/h Standard Deviation 22.09	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1026)	-8.6 mm/h Standard Deviation 17.12	—
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1026)	-9.2 mm/h Standard Deviation 18.36	—
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1026)	-9.7 mm/h Standard Deviation 19.73	—
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1081)	-9.7 mm/h Standard Deviation 17.75	—
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1081)	-10.3 mm/h Standard Deviation 19.18	—
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1081)	-10.3 mm/h Standard Deviation 20.90	—
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1127)	-9.8 mm/h Standard Deviation 18.35	—
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1127)	-11.1 mm/h Standard Deviation 20.70	—
Mean Change From Baseline in ESR by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1127)	-12.2 mm/h Standard Deviation 22.41	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in ESR by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1038)	-8.6 mm/h Standard Deviation 16.79	—
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1038)	-8.9 mm/h Standard Deviation 17.67	—
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1038)	-9.8 mm/h Standard Deviation 20.33	—
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1112)	-9.7 mm/h Standard Deviation 18.17	—
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1112)	-10.7 mm/h Standard Deviation 20.44	—
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1112)	-11.0 mm/h Standard Deviation 20.64	—
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1075)	-9.7 mm/h Standard Deviation 18.37	—
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1075)	-11.1 mm/h Standard Deviation 20.21	—
Mean Change From Baseline in ESR by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1075)	-11.4 mm/h Standard Deviation 22.30	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=314)	-10.1 mm/h Standard Deviation 18.24	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=314)	-9.9 mm/h Standard Deviation 20.03	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=223)	-9.3 mm/h Standard Deviation 17.51	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=223)	-9.4 mm/h Standard Deviation 19.35	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=223)	-10.7 mm/h Standard Deviation 22.22	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=397)	-8.0 mm/h Standard Deviation 14.88	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=397)	-8.6 mm/h Standard Deviation 18.01	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=397)	-8.0 mm/h Standard Deviation 18.68	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=59)	-6.3 mm/h Standard Deviation 12.82	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=59)	-4.8 mm/h Standard Deviation 16.93	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=59)	-6.2 mm/h Standard Deviation 20.00	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=423)	-9.1 mm/h Standard Deviation 17.40	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=423)	-9.2 mm/h Standard Deviation 18.24	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1963)	-9.7 mm/h Standard Deviation 18.40	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1963)	-10.8 mm/h Standard Deviation 20.04	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1963)	-11.7 mm/h Standard Deviation 21.57	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=423)	-10.1 mm/h Standard Deviation 21.17	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=454)	-9.0 mm/h Standard Deviation 16.61	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=454)	-9.8 mm/h Standard Deviation 18.60	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=454)	-10.1 mm/h Standard Deviation 18.73	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=418)	-8.2 mm/h Standard Deviation 16.42	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=418)	-9.2 mm/h Standard Deviation 19.44	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=418)	-7.6 mm/h Standard Deviation 20.91	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=324)	-10.3 mm/h Standard Deviation 18.11	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=324)	-10.6 mm/h Standard Deviation 19.52	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=324)	-9.7 mm/h Standard Deviation 20.95	—
Mean Change From Baseline in ESR by Smoking History at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=314)	-8.4 mm/h Standard Deviation 17.55	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=106)	-5.6 mm/h Standard Deviation 10.46	—
Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=106)	-5.0 mm/h Standard Deviation 10.87	—
Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=106)	-4.7 mm/h Standard Deviation 11.99	—
Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3174)	-9.5 mm/h Standard Deviation 17.94	—
Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3174)	-10.4 mm/h Standard Deviation 19.70	—
Mean Change From Baseline in ESR by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3174)	-10.9 mm/h Standard Deviation 21.29	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1212)	-11.2 mm/h Standard Deviation 19.25	—
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1212)	-11.4 mm/h Standard Deviation 21.53	—
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1212)	-10.1 mm/h Standard Deviation 18.15	—
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=1009)	-9.6 mm/h Standard Deviation 18.27	—
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=1009)	-11.3 mm/h Standard Deviation 20.44	—
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=1009)	-11.8 mm/h Standard Deviation 21.58	—
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1054)	-8.2 mm/h Standard Deviation 16.79	—
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1054)	-8.0 mm/h Standard Deviation 18.73	—
Mean Change From Baseline in ESR by Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1054)	-8.9 mm/h Standard Deviation 19.96	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1305)	-8.6 mm/h Standard Deviation 17.45	—
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1305)	-9.4 mm/h Standard Deviation 19.02	—
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1305)	-9.9 mm/h Standard Deviation 20.85	—
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1105)	-9.6 mm/h Standard Deviation 18.39	—
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1105)	-10.7 mm/h Standard Deviation 20.44	—
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1105)	-11.8 mm/h Standard Deviation 22.27	—
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=850)	-10.2 mm/h Standard Deviation 17.49	—
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=850)	-10.9 mm/h Standard Deviation 19.13	—
Mean Change From Baseline in ESR by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=850)	-10.6 mm/h Standard Deviation 19.95	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1160)	-8.8 mm/h Standard Deviation 18.10	—
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1160)	-10.7 mm/h Standard Deviation 19.43	—
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1160)	-9.9 mm/h Standard Deviation 21.87	—
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1745)	-9.7 mm/h Standard Deviation 17.65	—
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1745)	-9.6 mm/h Standard Deviation 19.76	—
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1745)	-11.0 mm/h Standard Deviation 20.90	—
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=355)	-9.7 mm/h Standard Deviation 17.44	—
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=355)	-11.5 mm/h Standard Deviation 18.81	—
Mean Change From Baseline in ESR by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=355)	-12.0 mm/h Standard Deviation 19.62	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1056)	-8.9 mm/h Standard Deviation 18.47	—
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1056)	-9.2 mm/h Standard Deviation 19.18	—
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1056)	-9.5 mm/h Standard Deviation 20.50	—
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1061)	-9.8 mm/h Standard Deviation 16.19	—
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1061)	-10.9 mm/h Standard Deviation 19.55	—
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1061)	-11.5 mm/h Standard Deviation 21.16	—
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1097)	-9.2 mm/h Standard Deviation 17.96	—
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1097)	-10.0 mm/h Standard Deviation 19.33	—
Mean Change From Baseline in ESR by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1097)	-10.9 mm/h Standard Deviation 21.02	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum ESR by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=966)	-9.4 mm/h Standard Deviation 17.70	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=966)	-10.0 mm/h Standard Deviation 19.15	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=966)	-10.9 mm/h Standard Deviation 21.33	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=40)	-16.9 mm/h Standard Deviation 20.16	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=40)	-17.0 mm/h Standard Deviation 23.02	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=40)	-13.0 mm/h Standard Deviation 26.66	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=325)	-8.8 mm/h Standard Deviation 19.09	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=325)	-10.1 mm/h Standard Deviation 20.39	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=325)	-11.6 mm/h Standard Deviation 21.77	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1932)	-9.3 mm/h Standard Deviation 17.54	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1932)	-10.3 mm/h Standard Deviation 19.45	—
Mean Change From Baseline in ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1932)	-10.5 mm/h Standard Deviation 20.73	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The change from baseline in participant serum CRP was calculated by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1967)	-5.76 mg/L Standard Deviation 19.045	—
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=138)	-6.43 mg/L Standard Deviation 15.483	—
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=138)	-4.97 mg/L Standard Deviation 19.260	—
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=138)	-6.61 mg/L Standard Deviation 17.632	—
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=519)	-7.14 mg/L Standard Deviation 17.591	—
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=519)	-6.54 mg/L Standard Deviation 20.221	—
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=519)	-5.93 mg/L Standard Deviation 23.755	—
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1967)	-5.52 mg/L Standard Deviation 18.452	—
Mean Change From Baseline in C-Reactive Protein (CRP) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1967)	-5.46 mg/L Standard Deviation 18.921	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by concomitant DMARD background treatment was calculated at study Month 2, Month 4, and Month 6. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1662)	-6.02 mg/L Standard Deviation 16.365	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1662)	-5.91 mg/L Standard Deviation 19.101	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=211)	-3.32 mg/L Standard Deviation 19.341	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1662)	-5.74 mg/L Standard Deviation 18.459	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=424)	-6.14 mg/L Standard Deviation 16.979	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=424)	-5.07 mg/L Standard Deviation 21.648	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=424)	-6.43 mg/L Standard Deviation 18.324	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=211)	-2.56 mg/L Standard Deviation 22.236	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=211)	-2.37 mg/L Standard Deviation 16.441	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=147)	-7.57 mg/L Standard Deviation 22.433	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=147)	-9.61 mg/L Standard Deviation 22.126	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=147)	-9.54 mg/L Standard Deviation 22.444	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=104)	-4.42 mg/L Standard Deviation 28.394	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=104)	-4.49 mg/L Standard Deviation 16.258	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=104)	-3.62 mg/L Standard Deviation 36.080	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=301)	-3.90 mg/L Standard Deviation 16.817	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=301)	-4.70 mg/L Standard Deviation 17.356	—
Mean Change From Baseline in CRP by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=301)	-4.08 mg/L Standard Deviation 19.620	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in serum CRP by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1187)	-5.14 mg/L Standard Deviation 15.017	—
Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1187)	-4.90 mg/L Standard Deviation 15.643	—
Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1187)	-5.00 mg/L Standard Deviation 18.391	—
Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2048)	-6.04 mg/L Standard Deviation 19.355	—
Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2048)	-5.98 mg/L Standard Deviation 20.850	—
Mean Change From Baseline in CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2048)	-6.20 mg/L Standard Deviation 20.738	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1118)	-6.38 mg/L Standard Deviation 18.525	—
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1118)	-6.23 mg/L Standard Deviation 20.809	—
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1118)	-6.06 mg/L Standard Deviation 21.514	—
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1158)	-5.20 mg/L Standard Deviation 17.550	—
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1158)	-4.89 mg/L Standard Deviation 18.155	—
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1158)	-5.54 mg/L Standard Deviation 18.247	—
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=958)	-5.56 mg/L Standard Deviation 17.533	—
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=958)	-5.69 mg/L Standard Deviation 18.158	—
Mean Change From Baseline in CRP by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=958)	-5.69 mg/L Standard Deviation 19.959	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the participant serum CRP by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=756)	-6.42 mg/L Standard Deviation 20.069	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=885)	-5.84 mg/L Standard Deviation 18.067	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=885)	-5.40 mg/L Standard Deviation 21.661	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=885)	-6.03 mg/L Standard Deviation 21.956	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=756)	-6.23 mg/L Standard Deviation 19.018	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=756)	-6.15 mg/L Standard Deviation 20.592	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=681)	-4.73 mg/L Standard Deviation 15.933	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=681)	-4.49 mg/L Standard Deviation 18.010	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=681)	-5.15 mg/L Standard Deviation 16.892	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=912)	-5.73 mg/L Standard Deviation 17.183	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=912)	-6.05 mg/L Standard Deviation 17.284	—
Mean Change From Baseline in CRP by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=912)	-5.63 mg/L Standard Deviation 19.402	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. DAS28-ESR scores of \> 3.2 to \<=5.1 indicate moderate disease activity and DAS28-ESR scores of \> 5.1 indicate high disease activity.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=687)	-3.07 mg/L Standard Deviation 11.053	—
Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=687)	-1.61 mg/L Standard Deviation 13.582	—
Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=687)	-1.57 mg/L Standard Deviation 13.418	—
Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2538)	-6.43 mg/L Standard Deviation 19.287	—
Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2538)	-6.67 mg/L Standard Deviation 20.241	—
Mean Change From Baseline in CRP by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2538)	-6.89 mg/L Standard Deviation 21.215	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1025)	-5.18 mg/L Standard Deviation 16.961	—
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1025)	-4.63 mg/L Standard Deviation 18.781	—
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1025)	-5.19 mg/L Standard Deviation 18.356	—
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1079)	-6.12 mg/L Standard Deviation 15.703	—
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1079)	-5.89 mg/L Standard Deviation 17.219	—
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1079)	-5.46 mg/L Standard Deviation 21.063	—
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1125)	-5.85 mg/L Standard Deviation 20.488	—
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1125)	-6.21 mg/L Standard Deviation 21.056	—
Mean Change From Baseline in CRP by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1125)	-6.59 mg/L Standard Deviation 20.170	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in CRP by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1027)	-5.03 mg/L Standard Deviation 18.512	—
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1101)	-5.95 mg/L Standard Deviation 17.423	—
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1101)	-5.73 mg/L Standard Deviation 18.955	—
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1027)	-5.16 mg/L Standard Deviation 17.703	—
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1027)	-4.79 mg/L Standard Deviation 19.454	—
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1101)	-5.60 mg/L Standard Deviation 18.699	—
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1070)	-6.00 mg/L Standard Deviation 18.651	—
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1070)	-6.22 mg/L Standard Deviation 19.067	—
Mean Change From Baseline in CRP by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1070)	-6.60 mg/L Standard Deviation 22.345	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1941)	-6.00 mg/L Standard Deviation 18.946	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1941)	-5.96 mg/L Standard Deviation 20.052	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1941)	-6.27 mg/L Standard Deviation 21.278	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=318)	-5.33 mg/L Standard Deviation 13.490	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=318)	-4.42 mg/L Standard Deviation 18.329	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=318)	-3.70 mg/L Standard Deviation 16.922	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=312)	-5.88 mg/L Standard Deviation 19.794	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=312)	-6.50 mg/L Standard Deviation 17.869	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=312)	-7.38 mg/L Standard Deviation 19.301	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=218)	-4.28 mg/L Standard Deviation 16.141	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=218)	-4.85 mg/L Standard Deviation 18.384	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=218)	-4.72 mg/L Standard Deviation 15.013	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=388)	-5.61 mg/L Standard Deviation 13.870	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=388)	-4.88 mg/L Standard Deviation 15.045	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=388)	-4.57 mg/L Standard Deviation 18.217	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=58)	-3.44 mg/L Standard Deviation 21.229	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=58)	-1.86 mg/L Standard Deviation 23.322	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=58)	-2.76 mg/L Standard Deviation 19.927	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=418)	-6.13 mg/L Standard Deviation 18.761	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=418)	-5.91 mg/L Standard Deviation 18.169	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=418)	-6.75 mg/L Standard Deviation 18.752	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=450)	-4.73 mg/L Standard Deviation 13.845	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=450)	-4.63 mg/L Standard Deviation 16.089	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=450)	-4.60 mg/L Standard Deviation 15.440	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=405)	-4.92 mg/L Standard Deviation 15.558	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=405)	-4.40 mg/L Standard Deviation 18.166	—
Mean Change From Baseline in CRP by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=405)	-3.48 mg/L Standard Deviation 18.229	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=105)	-2.92 mg/L Standard Deviation 10.633	—
Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=105)	-2.74 mg/L Standard Deviation 11.237	—
Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=105)	-3.16 mg/L Standard Deviation 10.453	—
Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3130)	-5.81 mg/L Standard Deviation 18.078	—
Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3130)	-5.68 mg/L Standard Deviation 19.314	—
Mean Change From Baseline in CRP by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3130)	-5.85 mg/L Standard Deviation 20.146	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=995)	-6.61 mg/L Standard Deviation 18.586	—
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1201)	-5.83 mg/L Standard Deviation 15.963	—
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1201)	-5.58 mg/L Standard Deviation 17.902	—
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1201)	-5.83 mg/L Standard Deviation 17.496	—
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=995)	-6.66 mg/L Standard Deviation 21.059	—
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=995)	-6.47 mg/L Standard Deviation 22.984	—
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1034)	-4.69 mg/L Standard Deviation 19.286	—
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1034)	-4.51 mg/L Standard Deviation 18.487	—
Mean Change From Baseline in CRP by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1034)	-5.00 mg/L Standard Deviation 19.364	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1284)	-5.17 mg/L Standard Deviation 17.628	—
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1284)	-5.29 mg/L Standard Deviation 17.491	—
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1284)	-5.77 mg/L Standard Deviation 20.401	—
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1094)	-5.60 mg/L Standard Deviation 19.412	—
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1094)	-5.58 mg/L Standard Deviation 20.544	—
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1094)	-5.65 mg/L Standard Deviation 20.715	—
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=837)	-6.71 mg/L Standard Deviation 16.262	—
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=837)	-6.03 mg/L Standard Deviation 19.794	—
Mean Change From Baseline in CRP by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=837)	-5.96 mg/L Standard Deviation 18.132	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1147)	-5.40 mg/L Standard Deviation 16.834	—
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1147)	-5.53 mg/L Standard Deviation 18.865	—
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1147)	-6.38 mg/L Standard Deviation 18.656	—
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1717)	-5.95 mg/L Standard Deviation 18.516	—
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1717)	-5.59 mg/L Standard Deviation 19.658	—
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1717)	-5.42 mg/L Standard Deviation 20.802	—
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=351)	-5.58 mg/L Standard Deviation 18.496	—
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=351)	-5.68 mg/L Standard Deviation 17.691	—
Mean Change From Baseline in CRP by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=351)	-5.60 mg/L Standard Deviation 19.623	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1043)	-5.51 mg/L Standard Deviation 19.219	—
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1043)	-5.61 mg/L Standard Deviation 17.530	—
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1043)	-6.01 mg/L Standard Deviation 17.911	—
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1049)	-5.31 mg/L Standard Deviation 18.054	—
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1049)	-5.24 mg/L Standard Deviation 20.441	—
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1049)	-5.49 mg/L Standard Deviation 21.234	—
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1077)	-6.18 mg/L Standard Deviation 18.134	—
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1077)	-5.92 mg/L Standard Deviation 17.615	—
Mean Change From Baseline in CRP by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1077)	-5.81 mg/L Standard Deviation 20.194	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in participant serum CRP by the physician's expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=40)	-12.35 mg/L Standard Deviation 19.948	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=40)	-11.02 mg/L Standard Deviation 23.210	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=40)	-11.41 mg/L Standard Deviation 20.392	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=313)	-6.74 mg/L Standard Deviation 19.737	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=313)	-8.72 mg/L Standard Deviation 20.915	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=313)	-8.97 mg/L Standard Deviation 22.089	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1906)	-5.82 mg/L Standard Deviation 19.413	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1906)	-5.70 mg/L Standard Deviation 19.519	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1906)	-5.86 mg/L Standard Deviation 20.553	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=959)	-4.80 mg/L Standard Deviation 13.488	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=959)	-4.13 mg/L Standard Deviation 17.227	—
Mean Change From Baseline in CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=959)	-4.32 mg/L Standard Deviation 17.589	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in physician global assessment of disease activity was calculated by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=142)	-24.6 Score on a Scale Standard Deviation 19.80	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=142)	-32.1 Score on a Scale Standard Deviation 21.50	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=142)	-35.8 Score on a Scale Standard Deviation 22.02	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=523)	-25.9 Score on a Scale Standard Deviation 21.29	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=523)	-34.4 Score on a Scale Standard Deviation 21.19	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=523)	-38.2 Score on a Scale Standard Deviation 22.63	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1987)	-24.1 Score on a Scale Standard Deviation 20.53	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1987)	-32.9 Score on a Scale Standard Deviation 21.47	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1987)	-37.3 Score on a Scale Standard Deviation 22.93	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease by concomitant DMARD background treatment was evaluated at Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide only.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=149)	-39.7 Score on a Scale Standard Deviation 22.46	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=149)	-25.1 Score on a Scale Standard Deviation 20.53	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=149)	-34.5 Score on a Scale Standard Deviation 20.87	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=105)	-26.1 Score on a Scale Standard Deviation 21.63	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=105)	-33.5 Score on a Scale Standard Deviation 21.17	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=105)	-35.7 Score on a Scale Standard Deviation 22.58	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=302)	-25.4 Score on a Scale Standard Deviation 21.24	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=302)	-33.3 Score on a Scale Standard Deviation 22.52	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=302)	-37.3 Score on a Scale Standard Deviation 23.02	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1674)	-24.7 Score on a Scale Standard Deviation 20.42	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1674)	-33.0 Score on a Scale Standard Deviation 21.63	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1674)	-36.5 Score on a Scale Standard Deviation 23.22	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=432)	-23.5 Score on a Scale Standard Deviation 21.44	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=432)	-33.5 Score on a Scale Standard Deviation 21.15	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=432)	-40.5 Score on a Scale Standard Deviation 21.00	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=215)	-23.9 Score on a Scale Standard Deviation 20.91	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=215)	-31.8 Score on a Scale Standard Deviation 21.43	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=215)	-37.1 Score on a Scale Standard Deviation 22.84	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1197)	-23.6 Score on a Scale Standard Deviation 20.09	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1197)	-32.3 Score on a Scale Standard Deviation 21.55	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1197)	-35.9 Score on a Scale Standard Deviation 23.12	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2069)	-25.0 Score on a Scale Standard Deviation 21.08	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2069)	-33.3 Score on a Scale Standard Deviation 21.66	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2069)	-37.8 Score on a Scale Standard Deviation 22.77	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1124)	-36.1 Score on a Scale Standard Deviation 23.85	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1124)	-24.7 Score on a Scale Standard Deviation 20.96	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1124)	-32.8 Score on a Scale Standard Deviation 22.34	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1171)	-24.5 Score on a Scale Standard Deviation 21.20	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1171)	-32.8 Score on a Scale Standard Deviation 20.79	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1171)	-37.7 Score on a Scale Standard Deviation 21.69	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=970)	-24.2 Score on a Scale Standard Deviation 19.89	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=970)	-33.2 Score on a Scale Standard Deviation 21.91	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=970)	-37.6 Score on a Scale Standard Deviation 23.24	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=895)	-23.5 Score on a Scale Standard Deviation 21.06	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=895)	-31.7 Score on a Scale Standard Deviation 22.44	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=895)	-35.3 Score on a Scale Standard Deviation 23.98	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=761)	-25.0 Score on a Scale Standard Deviation 20.76	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=761)	-33.4 Score on a Scale Standard Deviation 21.79	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=761)	-37.5 Score on a Scale Standard Deviation 22.13	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=688)	-23.6 Score on a Scale Standard Deviation 2128	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=688)	-32.4 Score on a Scale Standard Deviation 21.00	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=688)	-36.7 Score on a Scale Standard Deviation 22.90	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=921)	-25.7 Score on a Scale Standard Deviation 19.92	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=921)	-34.2 Score on a Scale Standard Deviation 21.10	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=921)	-38.7 Score on a Scale Standard Deviation 22.39	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=696)	-21.3 Score on a Scale Standard Deviation 19.24	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=696)	-27.4 Score on a Scale Standard Deviation 20.01	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=696)	-30.5 Score on a Scale Standard Deviation 20.35	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2560)	-25.4 Score on a Scale Standard Deviation 21.00	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2560)	-34.4 Score on a Scale Standard Deviation 21.81	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2560)	-38.9 Score on a Scale Standard Deviation 23.24	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1023)	-21.9 Score on a Scale Standard Deviation 20.57	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1023)	-29.9 Score on a Scale Standard Deviation 21.63	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1023)	-34.2 Score on a Scale Standard Deviation 22.90	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1077)	-23.9 Score on a Scale Standard Deviation 20.35	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1077)	-32.4 Score on a Scale Standard Deviation 21.51	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1077)	-36.5 Score on a Scale Standard Deviation 22.72	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1120)	-27.5 Score on a Scale Standard Deviation 20.91	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1120)	-36.3 Score on a Scale Standard Deviation 21.17	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1120)	-40.5 Score on a Scale Standard Deviation 22.58	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

Population: The efficacy evaluable population comprised all participants with a baseline DAS28-ESR or at least one post-baseline measurement of DAS28-ESR. n values represent the number of participants at baseline.

The mean change from baseline in the physician global assessment of disease activity by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1035)	-21.6 Score on a Scale Standard Deviation 20.82	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1035)	-30.4 Score on a Scale Standard Deviation 22.23	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1035)	-34.6 Score on a Scale Standard Deviation 23.64	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1105)	-24.6 Score on a Scale Standard Deviation 20.60	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1105)	-33.0 Score on a Scale Standard Deviation 21.29	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1105)	-36.7 Score on a Scale Standard Deviation 22.92	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1071)	-27.1 Score on a Scale Standard Deviation 20.62	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1071)	-35.2 Score on a Scale Standard Deviation 21.23	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1071)	-40.2 Score on a Scale Standard Deviation 21.96	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by participant baseline smoking status was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=222)	-31.0 Score on a Scale Standard Deviation 22.71	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1954)	-25.0 Score on a Scale Standard Deviation 20.86	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1954)	-33.9 Score on a Scale Standard Deviation 21.26	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1954)	-38.3 Score on a Scale Standard Deviation 22.38	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=323)	-26.5 Score on a Scale Standard Deviation 19.97	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=323)	-34.3 Score on a Scale Standard Deviation 21.45	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=323)	-38.7 Score on a Scale Standard Deviation 21.91	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=313)	-25.3 Score on a Scale Standard Deviation 20.78	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=313)	-33.1 Score on a Scale Standard Deviation 21.79	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=313)	-37.1 Score on a Scale Standard Deviation 24.62	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=222)	-22.0 Score on a Scale Standard Deviation 19.85	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=222)	-34.8 Score on a Scale Standard Deviation 24.11	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=395)	-21.6 Score on a Scale Standard Deviation 20.33	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=395)	-28.6 Score on a Scale Standard Deviation 22.11	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=395)	-31.6 Score on a Scale Standard Deviation 23.62	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=59)	-22.7 Score on a Scale Standard Deviation 24.16	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=59)	-28.9 Score on a Scale Standard Deviation 22.61	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=59)	-34.2 Score on a Scale Standard Deviation 21.29	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=422)	-24.8 Score on a Scale Standard Deviation 20.94	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=422)	-32.8 Score on a Scale Standard Deviation 22.77	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=422)	-36.7 Score on a Scale Standard Deviation 24.61	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=451)	-23.2 Score on a Scale Standard Deviation 19.99	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=451)	-31.5 Score on a Scale Standard Deviation 20.84	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=451)	-34.8 Score on a Scale Standard Deviation 23.22	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=417)	-23.7 Score on a Scale Standard Deviation 20.75	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=417)	-30.3 Score on a Scale Standard Deviation 22.73	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=417)	-34.6 Score on a Scale Standard Deviation 22.86	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=105)	-22.0 Score on a Scale Standard Deviation 18.89	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=105)	-27.9 Score on a Scale Standard Deviation 19.21	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=105)	-31.6 Score on a Scale Standard Deviation 20.66	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3161)	-24.6 Score on a Scale Standard Deviation 20.79	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3161)	-33.1 Score on a Scale Standard Deviation 21.68	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3161)	-37.3 Score on a Scale Standard Deviation 22.96	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] -100mm \[worst\]) with increasing scores indicating increased level of disease. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1208)	-26.4 Score on a Scale Standard Deviation 21.50	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1208)	-34.7 Score on a Scale Standard Deviation 22.21	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1208)	-39.2 Score on a Scale Standard Deviation 23.01	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=1005)	-25.2 Score on a Scale Standard Deviation 20.46	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=1005)	-34.3 Score on a Scale Standard Deviation 21.06	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=1005)	-38.0 Score on a Scale Standard Deviation 22.25	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1049)	-21.6 Score on a Scale Standard Deviation 19.79	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1049)	-29.6 Score on a Scale Standard Deviation 21.11	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1049)	-33.8 Score on a Scale Standard Deviation 23.13	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by the treating physician level of experience was evaluated at study Month 2, Month 4, and Month 6. The participant global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1305)	-33.2 Score on a Scale Standard Deviation 21.86	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1305)	-23.7 Score on a Scale Standard Deviation 21.25	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1305)	-37.0 Score on a Scale Standard Deviation 23.43	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1101)	-25.6 Score on a Scale Standard Deviation 20.53	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1101)	-33.6 Score on a Scale Standard Deviation 21.50	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1101)	-38.8 Score on a Scale Standard Deviation 22.62	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=846)	-24.5 Score on a Scale Standard Deviation 20.05	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=846)	-31.9 Score on a Scale Standard Deviation 21.41	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=846)	-35.1 Score on a Scale Standard Deviation 22.25	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by physician experience level with biologics was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1159)	-23.5 Score on a Scale Standard Deviation 20.84	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1159)	-32.5 Score on a Scale Standard Deviation 21.94	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1159)	-37.3 Score on a Scale Standard Deviation 23.13	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1740)	-24.9 Score on a Scale Standard Deviation 20.80	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1740)	-33.2 Score on a Scale Standard Deviation 21.50	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1740)	-37.1 Score on a Scale Standard Deviation 22.86	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=353)	-26.4 Score on a Scale Standard Deviation 19.63	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=353)	-33.3 Score on a Scale Standard Deviation 21.24	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=353)	-36.6 Score on a Scale Standard Deviation 22.29	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by the number of patients treated with biologics by the treating physician was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1060)	-33.7 Units on a Scale Standard Deviation 21.96	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1060)	-37.0 Units on a Scale Standard Deviation 23.00	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1095)	-25.0 Units on a Scale Standard Deviation 21.38	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1095)	-32.7 Units on a Scale Standard Deviation 22.79	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1095)	-36.0 Units on a Scale Standard Deviation 23.67	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1053)	-23.1 Units on a Scale Standard Deviation 19.37	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1053)	-32.4 Units on a Scale Standard Deviation 20.04	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1053)	-38.3 Units on a Scale Standard Deviation 21.95	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1060)	-25.5 Units on a Scale Standard Deviation 21.04	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the physician global assessment of disease activity by the baseline physician expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The physician global assessment of disease activity was evaluated using a VAS (0mm \[best\] - 100mm \[worst\]) with increasing scores indicating increased level of disease. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=39)	-28.5 Units on a Scale Standard Deviation 18.27	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=39)	-37.3 Units on a Scale Standard Deviation 24.56	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=39)	-38.9 Units on a Scale Standard Deviation 28.37	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=325)	-24.1 Units on a Scale Standard Deviation 20.53	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=325)	-32.6 Units on a Scale Standard Deviation 22.50	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=325)	-37.4 Units on a Scale Standard Deviation 23.94	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1927)	-24.8 Units on a Scale Standard Deviation 20.72	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1927)	-33.6 Units on a Scale Standard Deviation 21.18	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1927)	-38.0 Units on a Scale Standard Deviation 22.40	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=966)	-24.0 Units on a Scale Standard Deviation 20.84	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=966)	-31.6 Units on a Scale Standard Deviation 21.96	—
Mean Change From Baseline in the Physician Global Assessment of Disease Activity by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=966)	-35.1 Units on a Scale Standard Deviation 23.21	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR was calculated by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=142)	-2.23 Score on a Scale Standard Deviation 1.358	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=526)	-1.43 Score on a Scale Standard Deviation 1.037	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=526)	-2.01 Score on a Scale Standard Deviation 1.252	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=526)	-2.35 Score on a Scale Standard Deviation 1.400	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1995)	-1.42 Score on a Scale Standard Deviation 1.131	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=142)	-1.40 Score on a Scale Standard Deviation 1.060	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=142)	-1.97 Score on a Scale Standard Deviation 1.271	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1995)	-2.00 Score on a Scale Standard Deviation 1.275	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1995)	-2.29 Score on a Scale Standard Deviation 1.376	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-ESR measures disease burden using patient global health (self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX+sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1681)	-1.44 Score on a Scale Standard Deviation 1.092	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1681)	-2.03 Score on a Scale Standard Deviation 1.279	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1681)	-2.32 Score on a Scale Standard Deviation 1.386	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=433)	-1.35 Score on a Scale Standard Deviation 1.163	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=433)	-1.94 Score on a Scale Standard Deviation 1.274	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=433)	-2.32 Score on a Scale Standard Deviation 1.329	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=216)	-1.42 Score on a Scale Standard Deviation 1.208	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=216)	-1.85 Score on a Scale Standard Deviation 1.280	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=216)	-2.10 Score on a Scale Standard Deviation 1.441	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=150)	-1.39 Score on a Scale Standard Deviation 1.059	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=150)	-2.12 Score on a Scale Standard Deviation 1.334	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=150)	-2.46 Score on a Scale Standard Deviation 1.493	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=106)	-1.46 Score on a Scale Standard Deviation 1.099	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=106)	-2.09 Score on a Scale Standard Deviation 1.148	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=106)	-2.18 Score on a Scale Standard Deviation 1.329	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=303)	-1.40 Score on a Scale Standard Deviation 1.098	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=303)	-1.90 Score on a Scale Standard Deviation 1.288	—
Mean Change From Baseline in DAS28-ESR Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=303)	-2.13 Score on a Scale Standard Deviation 1.352	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \<3.2 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1202)	-1.41 Score on a Scale Standard Deviation 1.079	—
Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1202)	-2.00 Score on a Scale Standard Deviation 1.233	—
Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1202)	-2.30 Score on a Scale Standard Deviation 1.380	—
Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2078)	-1.41 Score on a Scale Standard Deviation 1.123	—
Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2078)	-1.95 Score on a Scale Standard Deviation 1.291	—
Mean Change From Baseline in DAS28-ESR by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2078)	-2.24 Score on a Scale Standard Deviation 1.376	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed on a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1129)	-1.47 Score on a Scale Standard Deviation 1.142	—
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1129)	-2.05 Score on a Scale Standard Deviation 1.361	—
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1129)	-2.32 Score on a Scale Standard Deviation 1.471	—
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1176)	-1.41 Score on a Scale Standard Deviation 1.117	—
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1176)	-1.93 Score on a Scale Standard Deviation 1.254	—
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1176)	-2.26 Score on a Scale Standard Deviation 1.347	—
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=974)	-1.35 Score on a Scale Standard Deviation 1.050	—
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=974)	-1.92 Score on a Scale Standard Deviation 1.175	—
Mean Change From Baseline in DAS28-ESR Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=974)	-2.20 Score on a Scale Standard Deviation 1.301	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR score by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed on a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \>5.1 = high disease activity, DAS28-ESR \<3.2 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=899)	-1.39 Score on a Scale Standard Deviation 1.172	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=899)	-1.97 Score on a Scale Standard Deviation 1.380	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=899)	-2.25 Score on a Scale Standard Deviation 1.453	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=764)	-1.43 Score on a Scale Standard Deviation 1.100	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=764)	-1.97 Score on a Scale Standard Deviation 1.214	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=764)	-2.23 Score on a Scale Standard Deviation 1.361	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=692)	-1.40 Score on a Scale Standard Deviation 1.069	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=692)	-1.97 Score on a Scale Standard Deviation 1.204	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=692)	-2.25 Score on a Scale Standard Deviation 1.385	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=924)	-1.44 Score on a Scale Standard Deviation 1.076	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=924)	-1.97 Score on a Scale Standard Deviation 1.256	—
Mean Change From Baseline in DAS28-ESR Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=924)	-2.30 Score on a Scale Standard Deviation 1.311	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR score by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR with increasing scores indicating increased level of disease burden. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 to \< =5.1 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=698)	-1.10 Score on a Scale Standard Deviation 1.001	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=698)	-1.43 Score on a Scale Standard Deviation 1.085	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=698)	-1.61 Score on a Scale Standard Deviation 1.184	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2572)	-1.50 Score on a Scale Standard Deviation 1.111	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2572)	-2.12 Score on a Scale Standard Deviation 1.272	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2572)	-2.45 Score on a Scale Standard Deviation 1.368	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. Increasing scores indicate increased burden of disease. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1026)	-1.34 Score on a Scale Standard Deviation 1.140	—
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1026)	-1.90 Score on a Scale Standard Deviation 1.284	—
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1026)	-2.19 Score on a Scale Standard Deviation 1.427	—
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1081)	-1.41 Score on a Scale Standard Deviation 1.077	—
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1081)	-1.95 Score on a Scale Standard Deviation 1.249	—
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1081)	-2.21 Score on a Scale Standard Deviation 1.362	—
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1127)	-1.49 Score on a Scale Standard Deviation 1.106	—
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1127)	-2.06 Score on a Scale Standard Deviation 1.282	—
Mean Change From Baseline in DAS28-ESR Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1127)	-2.38 Score on a Scale Standard Deviation 1.347	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR score by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. Increasing scores indicate increased burden of disease. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1038)	-1.30 Score on a Scale Standard Deviation 1.120	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1038)	-1.85 Score on a Scale Standard Deviation 1.277	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1038)	-2.17 Score on a Scale Standard Deviation 1.424	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1112)	-1.46 Score on a Scale Standard Deviation 1.071	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1112)	-2.04 Score on a Scale Standard Deviation 1.274	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1112)	-2.27 Score on a Scale Standard Deviation 1.371	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1075)	-1.48 Score on a Scale Standard Deviation 1.127	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1075)	-2.01 Score on a Scale Standard Deviation 1.261	—
Mean Change From Baseline in DAS28-ESR Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1075)	-2.35 Score on a Scale Standard Deviation 1.343	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1963)	-1.44 Score on a Scale Standard Deviation 1.111	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1963)	-2.04 Score on a Scale Standard Deviation 1.260	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1963)	-2.36 Score on a Scale Standard Deviation 1.341	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=324)	-1.44 Score on a Scale Standard Deviation 1.096	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=324)	-1.88 Score on a Scale Standard Deviation 1.227	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=324)	-2.23 Score on a Scale Standard Deviation 1.355	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=314)	-1.47 Score on a Scale Standard Deviation 1.18	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=314)	-1.99 Score on a Scale Standard Deviation 1.312	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=314)	-2.28 Score on a Scale Standard Deviation 1.399	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=223)	-1.26 Score on a Scale Standard Deviation 1.111	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=223)	-1.87 Score on a Scale Standard Deviation 1.309	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=223)	-2.17 Score on a Scale Standard Deviation 1.522	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=397)	-1.30 Score on a Scale Standard Deviation 1.032	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=397)	-1.76 Score on a Scale Standard Deviation 1.234	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=397)	-1.90 Score on a Scale Standard Deviation 1.376	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=59)	-1.31 Score on a Scale Standard Deviation 1.369	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=59)	-1.57 Score on a Scale Standard Deviation 1.465	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=59)	-1.77 Score on a Scale Standard Deviation 1.521	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=423)	-1.42 Score on a Scale Standard Deviation 1.158	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=423)	-1.94 Score on a Scale Standard Deviation 1.316	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=423)	-2.24 Score on a Scale Standard Deviation 1.463	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=454)	-1.41 Score on a Scale Standard Deviation 1.049	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=454)	-1.94 Score on a Scale Standard Deviation 1.247	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=454)	-2.16 Score on a Scale Standard Deviation 1.386	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=418)	-1.29 Score on a Scale Standard Deviation 1.071	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=418)	-1.69 Score on a Scale Standard Deviation 1.227	—
Mean Change From Baseline in DAS28-ESR Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=418)	-1.93 Score on a Scale Standard Deviation 1.380	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR score by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=106)	-1.29 Score on a Scale Standard Deviation 0.881	—
Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=106)	-1.87 Score on a Scale Standard Deviation 1.051	—
Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=106)	-1.86 Score on a Scale Standard Deviation 1.117	—
Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3174)	-1.42 Score on a Scale Standard Deviation 1.114	—
Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3174)	-1.97 Score on a Scale Standard Deviation 1.277	—
Mean Change From Baseline in DAS28-ESR Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3174)	-2.27 Score on a Scale Standard Deviation 1.383	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-ESR score by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1212)	-1.56 Score on a Scale Standard Deviation 1.132	—
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1212)	-2.11 Score on a Scale Standard Deviation 1.283	—
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1212)	-2.43 Score on a Scale Standard Deviation 1.377	—
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=1009)	-1.40 Score on a Scale Standard Deviation 1.094	—
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=1009)	-2.01 Score on a Scale Standard Deviation 1.288	—
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=1009)	-2.28 Score on a Scale Standard Deviation 1.386	—
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1054)	-1.25 Score on a Scale Standard Deviation 1.063	—
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1054)	-1.75 Score on a Scale Standard Deviation 1.208	—
Mean Change From Baseline in DAS28-ESR Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1054)	-2.04 Score on a Scale Standard Deviation 1.344	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=850)	-1.45 Score on a Scale Standard Deviation 1.127	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1305)	-1.35 Score on a Scale Standard Deviation 1.073	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1305)	-1.93 Score on a Scale Standard Deviation 1.240	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1305)	-2.20 Score on a Scale Standard Deviation 1.342	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1105)	-1.46 Score on a Scale Standard Deviation 1.126	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1105)	-2.03 Score on a Scale Standard Deviation 1.313	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1105)	-2.38 Score on a Scale Standard Deviation 1.423	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=850)	-1.95 Score on a Scale Standard Deviation 1.261	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=850)	-2.22 Score on a Scale Standard Deviation 1.359	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1160)	-1.36 Score on a Scale Standard Deviation 1.063	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1160)	-1.94 Score on a Scale Standard Deviation 1.237	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1160)	-2.22 Score on a Scale Standard Deviation 1.359	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1745)	-1.44 Score on a Scale Standard Deviation 1.124	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1745)	-1.97 Score on a Scale Standard Deviation 1.293	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1745)	-2.28 Score on a Scale Standard Deviation 1.385	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=355)	-1.46 Score on a Scale Standard Deviation 1.151	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=355)	-2.05 Score on a Scale Standard Deviation 1.269	—
Mean Change From Baseline in DAS28-ESR Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=355)	-2.33 Score on a Scale Standard Deviation 1.389	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1056)	-1.34 Score on a Scale Standard Deviation 1.034	—
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1056)	-1.89 Score on a Scale Standard Deviation 1.154	—
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1056)	-2.26 Score on a Scale Standard Deviation 1.269	—
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1061)	-1.46 Score on a Scale Standard Deviation 1.095	—
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1061)	-2.01 Score on a Scale Standard Deviation 1.291	—
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1061)	-2.26 Score on a Scale Standard Deviation 1.392	—
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1097)	-1.44 Score on a Scale Standard Deviation 1.177	—
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1097)	-2.00 Score on a Scale Standard Deviation 1.350	—
Mean Change From Baseline in DAS28-ESR Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1097)	-2.27 Score on a Scale Standard Deviation 1.449	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-ESR measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the ESR. The DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 = low disease activity, and DAS28-ESR \<2.6 = remission. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=40)	-1.84 Score on a Scale Standard Deviation 1.388	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=40)	-2.28 Score on a Scale Standard Deviation 1.359	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=40)	-2.54 Score on a Scale Standard Deviation 1.638	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=325)	-1.24 Score on a Scale Standard Deviation 1.067	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=325)	-1.72 Score on a Scale Standard Deviation 1.160	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=325)	-2.06 Score on a Scale Standard Deviation 1.339	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1932)	-1.37 Score on a Scale Standard Deviation 1.070	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1932)	-1.95 Score on a Scale Standard Deviation 1.252	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1932)	-2.24 Score on a Scale Standard Deviation 1.361	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=966)	-1.54 Score on a Scale Standard Deviation 1.161	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=966)	-2.09 Score on a Scale Standard Deviation 1.322	—
Mean Change From Baseline in DAS28-ESR by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=966)	-2.37 Score on a Scale Standard Deviation 1.400	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP was calculated by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=138)	-1.34 Score on a Scale Standard Deviation 1.014	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=138)	-1.87 Score on a Scale Standard Deviation 1.184	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=138)	-2.18 Score on a Scale Standard Deviation 1.266	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=519)	-1.38 Score on a Scale Standard Deviation 1.011	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=519)	-1.94 Score on a Scale Standard Deviation 1.178	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=519)	-2.23 Score on a Scale Standard Deviation 1.339	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1967)	-1.34 Score on a Scale Standard Deviation 1.067	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1967)	-1.87 Score on a Scale Standard Deviation 1.215	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1967)	-2.16 Score on a Scale Standard Deviation 1.286	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts \& swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP \>5.1 =high disease activity, DAS28-CRP \<3.2=low disease activity, and DAS28-CRP \<2.6=remission. DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 =leflunomide.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1662)	-1.36 Score on a Scale Standard Deviation 1.032	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1662)	-1.90 Score on a Scale Standard Deviation 1.216	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1662)	-2.18 Score on a Scale Standard Deviation 1.305	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=424)	-1.32 Score on a Scale Standard Deviation 1.123	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=424)	-1.86 Score on a Scale Standard Deviation 1.252	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=424)	-2.21 Score on a Scale Standard Deviation 1.254	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=211)	-1.31 Score on a Scale Standard Deviation 1.168	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=211)	-1.76 Score on a Scale Standard Deviation 1.203	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=211)	-1.94 Score on a Scale Standard Deviation 1.308	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=147)	-1.33 Score on a Scale Standard Deviation 1.022	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=147)	-1.92 Score on a Scale Standard Deviation 1.153	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=147)	-2.33 Score on a Scale Standard Deviation 1.361	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=104)	-1.39 Score on a Scale Standard Deviation 1.019	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=104)	-1.95 Score on a Scale Standard Deviation 1.127	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=104)	-2.10 Score on a Scale Standard Deviation 1.303	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=301)	-1.35 Score on a Scale Standard Deviation 1.029	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=301)	-1.86 Score on a Scale Standard Deviation 1.216	—
Mean Change From Baseline in DAS28-CRP Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=301)	-2.06 Score on a Scale Standard Deviation 1.279	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1187)	-1.34 Score on a Scale Standard Deviation 1.013	—
Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1187)	-1.86 Score on a Scale Standard Deviation 1.152	—
Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1187)	-2.16 Score on a Scale Standard Deviation 1.289	—
Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2048)	-1.35 Score on a Scale Standard Deviation 1.072	—
Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2048)	-1.86 Score on a Scale Standard Deviation 1.237	—
Mean Change From Baseline in DAS28-CRP by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2048)	-2.14 Score on a Scale Standard Deviation 1.297	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP score by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1118)	-1.39 Score on a Scale Standard Deviation 1.082	—
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1118)	-1.91 Score on a Scale Standard Deviation 1.288	—
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1118)	-2.19 Score on a Scale Standard Deviation 1.366	—
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1158)	-1.35 Score on a Scale Standard Deviation 1.064	—
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1158)	-1.83 Score on a Scale Standard Deviation 1.186	—
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1158)	-2.13 Score on a Scale Standard Deviation 1.271	—
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=958)	-1.30 Score on a Scale Standard Deviation 0.993	—
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=958)	-1.84 Score on a Scale Standard Deviation 1.128	—
Mean Change From Baseline in DAS28-CRP Score by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=958)	-2.12 Score on a Scale Standard Deviation 1.234	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP score by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=885)	-1.31 Score on a Scale Standard Deviation 1.113	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=885)	-1.82 Score on a Scale Standard Deviation 1.296	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=885)	-2.10 Score on a Scale Standard Deviation 1.353	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=756)	-1.38 Score on a Scale Standard Deviation 1.042	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=756)	-1.90 Score on a Scale Standard Deviation 1.169	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=756)	-2.16 Score on a Scale Standard Deviation 1.278	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=681)	-1.33 Score on a Scale Standard Deviation 1.022	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=681)	-1.87 Score on a Scale Standard Deviation 1.148	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=681)	-2.12 Score on a Scale Standard Deviation 1.298	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=912)	-1.37 Score on a Scale Standard Deviation 1.016	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=912)	-1.87 Score on a Scale Standard Deviation 1.188	—
Mean Change From Baseline in DAS28-CRP Score by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=912)	-2.20 Score on a Scale Standard Deviation 1.243	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP score by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP with increasing scores indicating increased burden of disease. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-CRP \> 5.1 = high disease activity, DAS28-CRP \< 3.2 to \< =5.1 = low disease activity, and DAS28-CRP \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=687)	-1.06 Score on a Scale Standard Deviation 0.931	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=687)	-1.37 Score on a Scale Standard Deviation 1.025	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=687)	-1.55 Score on a Scale Standard Deviation 1.088	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2538)	-1.43 Score on a Scale Standard Deviation 1.063	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2538)	-2.00 Score on a Scale Standard Deviation 1.216	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2538)	-2.31 Score on a Scale Standard Deviation 1.296	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1025)	-1.23 Score on a Scale Standard Deviation 1.057	—
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1025)	-1.75 Score on a Scale Standard Deviation 1.200	—
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1025)	-2.02 Score on a Scale Standard Deviation 1.294	—
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1079)	-1.34 Score on a Scale Standard Deviation 1.017	—
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1079)	-1.85 Score on a Scale Standard Deviation 1.170	—
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1079)	-2.12 Score on a Scale Standard Deviation 1.280	—
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1125)	-1.45 Score on a Scale Standard Deviation 1.067	—
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1125)	-1.98 Score on a Scale Standard Deviation 1.238	—
Mean Change From Baseline in DAS28-CRP Score by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1125)	-2.29 Score on a Scale Standard Deviation 1.295	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP score by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1027)	-1.22 Score on a Scale Standard Deviation 1.048	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1027)	-1.73 Score on a Scale Standard Deviation 1.200	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1027)	-2.02 Score on a Scale Standard Deviation 1.285	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1101)	-1.38 Score on a Scale Standard Deviation 1.022	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1101)	-1.92 Score on a Scale Standard Deviation 1.208	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1101)	-2.16 Score on a Scale Standard Deviation 1.301	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1070)	-1.43 Score on a Scale Standard Deviation 1.072	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1070)	-1.92 Score on a Scale Standard Deviation 1.204	—
Mean Change From Baseline in DAS28-CRP Score by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1070)	-2.26 Score on a Scale Standard Deviation 1.284	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1941)	-1.38 Score on a Scale Standard Deviation 1.054	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1941)	-1.94 Score on a Scale Standard Deviation 1.195	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1941)	-2.26 Score on a Scale Standard Deviation 1.257	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=318)	-1.36 Score on a Scale Standard Deviation 1.036	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=318)	-1.74 Score on a Scale Standard Deviation 1.190	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=318)	-2.11 Score on a Scale Standard Deviation 1.309	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=312)	-1.41 Score on a Scale Standard Deviation 1.068	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=312)	-1.88 Score on a Scale Standard Deviation 1.266	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=312)	-2.15 Score on a Scale Standard Deviation 1.325	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=218)	-1.15 Score on a Scale Standard Deviation 1.037	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=218)	-1.76 Score on a Scale Standard Deviation 1.241	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=218)	-2.04 Score on a Scale Standard Deviation 1.364	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=388)	-1.22 Score on a Scale Standard Deviation 0.984	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=388)	-1.63 Score on a Scale Standard Deviation 1.155	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=388)	-1.77 Score on a Scale Standard Deviation 1.289	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=58)	-1.33 Score on a Scale Standard Deviation 1.246	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=58)	-1.55 Score on a Scale Standard Deviation 1.248	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=58)	-1.63 Score on a Scale Standard Deviation 1.386	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=418)	-1.34 Score on a Scale Standard Deviation 1.088	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=418)	-1.82 Score on a Scale Standard Deviation 1.239	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=418)	-2.12 Score on a Scale Standard Deviation 1.346	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=450)	-1.32 Score on a Scale Standard Deviation 1.021	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=450)	-1.83 Score on a Scale Standard Deviation 1.195	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=450)	-2.03 Score on a Scale Standard Deviation 1.319	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=405)	-1.22 Score on a Scale Standard Deviation 0.989	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=405)	-1.57 Score on a Scale Standard Deviation 1.148	—
Mean Change From Baseline in DAS28-CRP Score by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=405)	-1.81 Score on a Scale Standard Deviation 1.294	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP score by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=105)	-1.17 Score on a Scale Standard Deviation 0.867	—
Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=105)	-1.75 Score on a Scale Standard Deviation 0.982	—
Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=105)	-1.81 Score on a Scale Standard Deviation 1.086	—
Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3130)	-1.35 Score on a Scale Standard Deviation 1.056	—
Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3130)	-1.87 Score on a Scale Standard Deviation 1.213	—
Mean Change From Baseline in DAS28-CRP Score by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3130)	-2.16 Score on a Scale Standard Deviation 1.299	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the DAS28-CRP score by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1201)	-1.48 Score on a Scale Standard Deviation 1.081	—
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1201)	-1.97 Score on a Scale Standard Deviation 1.225	—
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1201)	-2.31 Score on a Scale Standard Deviation 1.285	—
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=995)	-1.35 Score on a Scale Standard Deviation 1.031	—
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=995)	-1.92 Score on a Scale Standard Deviation 1.212	—
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=995)	-2.16 Score on a Scale Standard Deviation 1.294	—
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1034)	-1.19 Score on a Scale Standard Deviation 1.006	—
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1034)	-1.67 Score on a Scale Standard Deviation 1.153	—
Mean Change From Baseline in DAS28-CRP Score by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1034)	-1.94 Score on a Scale Standard Deviation 1.278	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1284)	-1.30 Score on a Scale Standard Deviation 1.026	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1284)	-1.83 Score on a Scale Standard Deviation 1.171	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1284)	-2.12 Score on a Scale Standard Deviation 1.274	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1094)	-1.39 Score on a Scale Standard Deviation 1.051	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1094)	-1.93 Score on a Scale Standard Deviation 1.242	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1094)	-2.23 Score on a Scale Standard Deviation 1.305	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=837)	-1.36 Score on a Scale Standard Deviation 1.082	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=837)	-1.83 Score on a Scale Standard Deviation 1.208	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=837)	-2.09 Score on a Scale Standard Deviation 1.301	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1147)	-1.31 Score on a Scale Standard Deviation 1.028	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1147)	-1.83 Score on a Scale Standard Deviation 1.179	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1147)	-2.16 Score on a Scale Standard Deviation 1.281	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1717)	-1.37 Score on a Scale Standard Deviation 1.047	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1717)	-1.87 Score on a Scale Standard Deviation 1.220	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1717)	-2.14 Score on a Scale Standard Deviation 1.292	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=351)	-1.40 Score on a Scale Standard Deviation 1.126	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=351)	-1.93 Score on a Scale Standard Deviation 1.225	—
Mean Change From Baseline in DAS28-CRP Score by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=351)	-2.16 Score on a Scale Standard Deviation 1.337	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1043)	-1.31 Units on a Scale Standard Deviation 1.001	—
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1043)	-1.81 Units on a Scale Standard Deviation 1.111	—
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1043)	-2.21 Units on a Scale Standard Deviation 1.228	—
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1049)	-1.36 Units on a Scale Standard Deviation 1.040	—
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1049)	-1.88 Units on a Scale Standard Deviation 1.228	—
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1049)	-2.13 Units on a Scale Standard Deviation 1.297	—
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1077)	-1.38 Units on a Scale Standard Deviation 1.100	—
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1077)	-1.90 Units on a Scale Standard Deviation 1.269	—
Mean Change From Baseline in DAS28-CRP Score by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1077)	-2.11 Units on a Scale Standard Deviation 1.339	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The DAS28-CRP measures disease burden using patient global health (patient self-assessment), tender joint-counts and swollen joint-counts (up to 28), and the CRP. The DAS28-CRP is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). Increasing scores indicate increased burden of disease with DAS28-CRP\> 5.1 = high disease activity, DAS28-CRP \< 3.2 = low disease activity, and DAS28-CRP \<2.6 = remission. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=40)	-1.68 Score on a Scale Standard Deviation 1.084	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=40)	-2.10 Score on a Scale Standard Deviation 1.190	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=40)	-2.57 Score on a Scale Standard Deviation 1.485	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=313)	-1.19 Score on a Scale Standard Deviation 0.992	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=313)	-1.67 Score on a Scale Standard Deviation 1.104	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=313)	-1.96 Score on a Scale Standard Deviation 1.265	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1906)	-1.32 Score on a Scale Standard Deviation 1.037	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1906)	-1.85 Score on a Scale Standard Deviation 1.207	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1906)	-2.14 Score on a Scale Standard Deviation 1.300	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=959)	-1.44 Score on a Scale Standard Deviation 1.083	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=959)	-1.94 Score on a Scale Standard Deviation 1.224	—
Mean Change From Baseline in DAS28-CRP by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=959)	-2.20 Score on a Scale Standard Deviation 1.271	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI was calculated by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=138)	-15.55 Score on a Scale Standard Deviation 11.605	—
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=138)	-20.69 Score on a Scale Standard Deviation 13.346	—
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=138)	-23.81 Score on a Scale Standard Deviation 14.063	—
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=516)	-15.74 Score on a Scale Standard Deviation 11.579	—
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=516)	-21.38 Score on a Scale Standard Deviation 12.872	—
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=516)	-24.01 Score on a Scale Standard Deviation 13.992	—
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1959)	-14.99 Score on a Scale Standard Deviation 11.920	—
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1959)	-20.52 Score on a Scale Standard Deviation 13.061	—
Mean Change From Baseline in the Simplified Disease Activity Index (SDAI) Score by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1959)	-23.00 Score on a Scale Standard Deviation 13.743	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1655)	-15.22 Score on a Scale Standard Deviation 11.434	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1655)	-20.59 Score on a Scale Standard Deviation 12.977	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1655)	-23.07 Score on a Scale Standard Deviation 13.766	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=423)	-15.16 Score on a Scale Standard Deviation 12.811	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=423)	-21.02 Score on a Scale Standard Deviation 13.780	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=423)	-24.31 Score on a Scale Standard Deviation 13.540	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=210)	-14.64 Score on a Scale Standard Deviation 13.206	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=210)	-19.84 Score on a Scale Standard Deviation 13.763	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=210)	-21.41 Score on a Scale Standard Deviation 14.685	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=146)	-14.86 Score on a Scale Standard Deviation 11.590	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=146)	-21.52 Score on a Scale Standard Deviation 12.601	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=146)	-24.45 Score on a Scale Standard Deviation 14.879	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=103)	-15.63 Score on a Scale Standard Deviation 11.838	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=103)	-20.71 Score on a Scale Standard Deviation 11.925	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=103)	-21.67 Score on a Scale Standard Deviation 13.876	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=300)	-14.11 Score on a Scale Standard Deviation 11.443	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=300)	-19.70 Score on a Scale Standard Deviation 12.639	—
Mean Change From Baseline in SDAI Score by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=300)	-21.41 Score on a Scale Standard Deviation 13.670	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), patient and physician global assessment of disease activity (VAS 0 cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1182)	-14.86 Score on a Scale Standard Deviation 11.130	—
Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1182)	-20.20 Score on a Scale Standard Deviation 12.452	—
Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1182)	-22.50 Score on a Scale Standard Deviation 13.513	—
Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2039)	-15.12 Score on a Scale Standard Deviation 12.102	—
Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2039)	-20.54 Score on a Scale Standard Deviation 13.367	—
Mean Change From Baseline in SDAI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2039)	-23.12 Score on a Scale Standard Deviation 13.962	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1113)	-15.69 Score on a Scale Standard Deviation 11.955	—
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1113)	-20.82 Score on a Scale Standard Deviation 13.873	—
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1113)	-23.31 Score on a Scale Standard Deviation 14.472	—
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1153)	-14.97 Score on a Scale Standard Deviation 11.902	—
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1153)	-20.26 Score on a Scale Standard Deviation 12.712	—
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1153)	-22.74 Score on a Scale Standard Deviation 13.451	—
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=954)	-14.33 Score on a Scale Standard Deviation 11.303	—
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=954)	-20.12 Score on a Scale Standard Deviation 12.421	—
Mean Change From Baseline in SDAI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=954)	-22.60 Score on a Scale Standard Deviation 13.430	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=753)	-23.12 Score on a Scale Standard Deviation 13.619	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=881)	-14.62 Score on a Scale Standard Deviation 12.465	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=881)	-19.74 Score on a Scale Standard Deviation 13.904	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=881)	-22.04 Score on a Scale Standard Deviation 14.136	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=753)	-15.37 Score on a Scale Standard Deviation 11.745	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=753)	-20.84 Score on a Scale Standard Deviation 12.672	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=677)	-14.75 Score on a Scale Standard Deviation 11.368	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=677)	-20.50 Score on a Scale Standard Deviation 12.587	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=677)	-22.63 Score on a Scale Standard Deviation 13.893	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=909)	-15.35 Score on a Scale Standard Deviation 11.331	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=909)	-20.65 Score on a Scale Standard Deviation 12.804	—
Mean Change From Baseline in SDAI by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=909)	-23.71 Score on a Scale Standard Deviation 13.516	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease with increasing scores indicating increased burden of disease. DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 to \< =5.1 = low disease activity, and DAS28-ESR \<2.6 = remission. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=685)	-9.34 Score on a Scale Standard Deviation 8.351	—
Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=685)	-12.20 Score on a Scale Standard Deviation 8.638	—
Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=685)	-13.42 Score on a Scale Standard Deviation 8.997	—
Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2526)	-16.61 Score on a Scale Standard Deviation 12.035	—
Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2526)	-22.66 Score on a Scale Standard Deviation 13.121	—
Mean Change From Baseline in SDAI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2526)	-25.48 Score on a Scale Standard Deviation 13.745	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1022)	-13.31 Score on a Scale Standard Deviation 11.369	—
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1022)	-18.68 Score on a Scale Standard Deviation 12.690	—
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1022)	-21.03 Score on a Scale Standard Deviation 13.335	—
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1075)	-14.73 Score on a Scale Standard Deviation 11.288	—
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1075)	-19.89 Score on a Scale Standard Deviation 12.479	—
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1075)	-22.09 Score on a Scale Standard Deviation 13.315	—
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1118)	-16.88 Score on a Scale Standard Deviation 12.288	—
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1118)	-22.53 Score on a Scale Standard Deviation 13.618	—
Mean Change From Baseline in SDAI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1118)	-25.38 Score on a Scale Standard Deviation 14.328	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1024)	-13.40 Score on a Scale Standard Deviation 11.370	—
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1024)	-18.92 Score on a Scale Standard Deviation 12.860	—
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1024)	-21.41 Score on a Scale Standard Deviation 13.526	—
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1094)	-15.39 Score on a Scale Standard Deviation 11.601	—
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1094)	-21.01 Score on a Scale Standard Deviation 12.787	—
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1094)	-22.89 Score on a Scale Standard Deviation 13.718	—
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1066)	-16.23 Score on a Scale Standard Deviation 12.156	—
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1066)	-21.23 Score on a Scale Standard Deviation 13.436	—
Mean Change From Baseline in SDAI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1066)	-24.38 Score on a Scale Standard Deviation 14.046	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=417)	-20.22 Score on a Scale Standard Deviation 13.138	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=417)	-22.30 Score on a Scale Standard Deviation 14.299	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=447)	-14.06 Score on a Scale Standard Deviation 11.024	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=447)	-19.43 Score on a Scale Standard Deviation 12.462	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=447)	-20.97 Score on a Scale Standard Deviation 13.912	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=404)	-13.27 Score on a Scale Standard Deviation 10.943	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=404)	-17.00 Score on a Scale Standard Deviation 12.278	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=404)	-19.27 Score on a Scale Standard Deviation 13.313	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1932)	-15.64 Score on a Scale Standard Deviation 11.959	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1932)	-21.45 Score on a Scale Standard Deviation 13.082	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1932)	-24.25 Score on a Scale Standard Deviation 13.565	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=317)	-15.10 Score on a Scale Standard Deviation 11.260	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=317)	-19.34 Score on a Scale Standard Deviation 13.177	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=317)	-22.54 Score on a Scale Standard Deviation 14.104	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=311)	-15.16 Score on a Scale Standard Deviation 11.477	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=311)	-19.81 Score on a Scale Standard Deviation 12.777	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=311)	-22.09 Score on a Scale Standard Deviation 13.648	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=217)	-13.29 Score on a Scale Standard Deviation 11.523	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=217)	-19.75 Score on a Scale Standard Deviation 12.965	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=217)	-21.63 Score on a Scale Standard Deviation 13.986	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=386)	-12.85 Score on a Scale Standard Deviation 10.766	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=386)	-17.31 Score on a Scale Standard Deviation 12.300	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=386)	-18.53 Score on a Scale Standard Deviation 13.500	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=58)	-14.23 Score on a Scale Standard Deviation 14.048	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=58)	-17.48 Score on a Scale Standard Deviation 13.194	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=58)	-17.91 Score on a Scale Standard Deviation 14.453	—
Mean Change From Baseline in SDAI by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=417)	-15.03 Score on a Scale Standard Deviation 11.772	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=104)	-12.10 Score on a Scale Standard Deviation 9.033	—
Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=104)	-17.08 Score on a Scale Standard Deviation 10.679	—
Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=104)	-17.50 Score on a Scale Standard Deviation 11.278	—
Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible- Month 2 (n=3117)	-15.12 Score on a Scale Standard Deviation 11.823	—
Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3117)	-20.52 Score on a Scale Standard Deviation 13.094	—
Mean Change From Baseline in SDAI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3117)	-23.07 Score on a Scale Standard Deviation 13.841	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the SDAI by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1197)	-16.51 Score on a Scale Standard Deviation 12.063	—
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1197)	-21.74 Score on a Scale Standard Deviation 13.182	—
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1197)	-24.42 Score on a Scale Standard Deviation 13.894	—
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=991)	-15.24 Score on a Scale Standard Deviation 11.600	—
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=991)	-21.04 Score on a Scale Standard Deviation 13.244	—
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=991)	-23.20 Score on a Scale Standard Deviation 13.816	—
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1029)	-13.09 Score on a Scale Standard Deviation 11.276	—
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1029)	-18.24 Score on a Scale Standard Deviation 12.411	—
Mean Change From Baseline in SDAI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1029)	-20.76 Score on a Scale Standard Deviation 13.431	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1284)	-14.49 Score on a Scale Standard Deviation 11.734	—
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1284)	-20.20 Score on a Scale Standard Deviation 12.818	—
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1284)	-22.60 Score on a Scale Standard Deviation 13.587	—
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1090)	-15.62 Score on a Scale Standard Deviation 11.857	—
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1090)	-20.95 Score on a Scale Standard Deviation 13.465	—
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1090)	-23.71 Score on a Scale Standard Deviation 13.926	—
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=833)	-15.10 Score on a Scale Standard Deviation 11.571	—
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=833)	-20.13 Score on a Scale Standard Deviation 12.810	—
Mean Change From Baseline in SDAI by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=833)	-22.32 Score on a Scale Standard Deviation 13.857	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1146)	-14.71 Score on a Scale Standard Deviation 11.851	—
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1146)	-20.41 Score on a Scale Standard Deviation 13.109	—
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1146)	-23.43 Score on a Scale Standard Deviation 13.784	—
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1712)	-15.25 Score on a Scale Standard Deviation 11.694	—
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1712)	-20.50 Score on a Scale Standard Deviation 13.078	—
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1712)	-22.75 Score on a Scale Standard Deviation 13.831	—
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=349)	-14.99 Score on a Scale Standard Deviation 11.616	—
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=349)	-20.17 Score on a Scale Standard Deviation 12.644	—
Mean Change From Baseline in SDAI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=349)	-21.93 Score on a Scale Standard Deviation 13.491	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1040)	-14.80 Score on a Scale Standard Deviation 11.566	—
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1040)	-20.65 Score on a Scale Standard Deviation 12.437	—
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1040)	-24.32 Score on a Scale Standard Deviation 13.447	—
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1048)	-15.32 Score on a Scale Standard Deviation 11.736	—
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1048)	-20.51 Score on a Scale Standard Deviation 13.421	—
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1048)	-22.65 Score on a Scale Standard Deviation 13.603	—
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1075)	-15.05 Score on a Scale Standard Deviation 11.797	—
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1075)	-20.19 Score on a Scale Standard Deviation 13.201	—
Mean Change From Baseline in SDAI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1075)	-21.88 Score on a Scale Standard Deviation 14.015	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count (28-joint assessment), patient and physician global assessment of disease activity (VAS 0cm \[best\] - 10 cm \[worst\]) and level of C-reactive protein (mg/dL, normal \<1 mg/dL) with increasing scores indicating increased level of disease. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=959)	-15.16 Score on a Scale Standard Deviation 11.560	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=39)	-19.26 Score on a Scale Standard Deviation 11.686	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=39)	-23.66 Score on a Scale Standard Deviation 11.626	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=39)	-27.55 Score on a Scale Standard Deviation 13.633	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=313)	-14.78 Score on a Scale Standard Deviation 11.904	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=313)	-20.39 Score on a Scale Standard Deviation 12.757	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=313)	-23.22 Score on a Scale Standard Deviation 14.029	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1901)	-14.93 Score on a Scale Standard Deviation 11.812	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1901)	-20.65 Score on a Scale Standard Deviation 13.258	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1901)	-23.33 Score on a Scale Standard Deviation 13.892	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=959)	-19.91 Score on a Scale Standard Deviation 12.675	—
Mean Change From Baseline in SDAI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=959)	-21.79 Score on a Scale Standard Deviation 13.418	—

SECONDARY outcome

Timeframe: Month 2, Month 4, Month 6

EULAR response was assessed at the end of Month 2, Month 4, and Month 6 by the Disease Activity Score using the 28 tender and swollen joint count calculated with erythrocyte sedimentation rate values (DAS28-ESR). A good response would was defined as a decrease \>1.2 units and a final DAS28-ESR \< 3.2 units, while a moderate response was defined as a decrease \> 1.2 units and final DAS28-ESR \>= 3.2 units, OR a decrease of 0.6 to 1.2.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Number of Participants Who Achieved DAS28-ESR EULAR Response Study Month 2	2127 Participants	—
Number of Participants Who Achieved DAS28-ESR EULAR Response Study Month 4	2522 Participants	—
Number of Participants Who Achieved DAS28-ESR EULAR Response Study Month 6	2692 Participants	—

SECONDARY outcome

Timeframe: Month 2, Month 4, Month 6

Population: The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.

DAS28-CRP EULAR response is defined as a good or moderate response that results in a DAS28-CRP \>=0.6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Number of Participants Who Achieved DAS28-CRP EULAR Response Study Month 2	2199 Participants	—
Number of Participants Who Achieved DAS28-CRP EULAR Response Study Month 4	2530 Participants	—
Number of Participants Who Achieved DAS28-CRP EULAR Response Study Month 6	2667 Participants	—

SECONDARY outcome

Timeframe: Month 2, Month 4, Month 6

Population: The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.

The number of participants achieving low disease activity or remission was calculated by the DAS28-ESR, DAS28-CRP, and SDAI at study Month 2, Month 4, and Month 6. Low disease activity by DAS28-ESR was defined as \>= 2.6 to 3.2, and remission was defined as a DAS28-ESR \<2.6. Low disease activity by DAS28-CRP was defined as DAS28-CRP \>=2.6 to 3.2, and remission was defined as DAS28-CRP \>2.6. Low disease activity by SDAI was defined as SDAI \>5.0 to \<=20, and remission was defined as SDAI \<=5.0.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by DAS28-ESR - Month 2	545 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by DAS28-ESR - Month 4	923 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by DAS28-ESR - Month 6	1228 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by DAS28-CRP - Month 2	805 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by DAS28-CRP - Month 4	1268 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by DAS28-CRP - Month 6	1624 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by SDAI - Month 2	671 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by SDAI - Month 4	1205 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Low Disease Activity by SDAI - Month 6	1585 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by DAS28-ESR - Month 2	251 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by DAS28-ESR - Month 4	527 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by DAS28-ESR - Month 6	784 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by DAS28-CRP - Month 2	380 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by DAS28-CRP - Month 4	765 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by DAS28-CRP - Month 6	1065 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by SDAI - Month 2	88 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by SDAI - Month 4	285 Participants	—
Number of Participants Achieving Low Disease Activity and Remission at Month 2, Month 4, and Month 6 Remission by SDAI - Month 6	464 Participants	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline the disability index of the HAQ was calculated by concomitant MTX dose (low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and high \>=15 mg/week) at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst)with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=142)	-0.35 Score on a Scale Standard Deviation 0.521	—
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=142)	-0.50 Score on a Scale Standard Deviation 0.547	—
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=142)	-0.58 Score on a Scale Standard Deviation 0.631	—
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=526)	-0.41 Score on a Scale Standard Deviation 0.533	—
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=526)	-0.54 Score on a Scale Standard Deviation 0.598	—
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=526)	-0.61 Score on a Scale Standard Deviation 0.651	—
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1993)	-0.37 Score on a Scale Standard Deviation 0.528	—
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1993)	-0.50 Score on a Scale Standard Deviation 0.613	—
Mean Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1993)	-0.56 Score on a Scale Standard Deviation 0.649	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). DMARD Combination 1 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2 = MTX + leflunomide; Combination 3 = MTX + sulfasalazine; Combination 4 = MTX + hydrochloroquine, chloroquine, chloroquine phosphate + sulfasalazine; Combination 5 = leflunomide.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1679)	-0.37 Score on a Scale Standard Deviation 0.521	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1679)	-0.50 Score on a Scale Standard Deviation 0.607	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1679)	-0.56 Score on a Scale Standard Deviation 0.651	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=433)	-0.40 Score on a Scale Standard Deviation 0.574	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=433)	-0.55 Score on a Scale Standard Deviation 0.633	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=433)	-0.62 Score on a Scale Standard Deviation 0.671	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=216)	-0.34 Score on a Scale Standard Deviation 0.531	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=216)	-0.43 Score on a Scale Standard Deviation 0.624	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=216)	-0.53 Score on a Scale Standard Deviation 0.588	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=150)	-0.36 Score on a Scale Standard Deviation 0.490	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=150)	-0.45 Score on a Scale Standard Deviation 0.523	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=150)	-0.55 Score on a Scale Standard Deviation 0.627	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=106)	-0.38 Score on a Scale Standard Deviation 0.501	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=106)	-0.67 Score on a Scale Standard Deviation 0.599	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=106)	-0.63 Score on a Scale Standard Deviation 0.709	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=303)	-0.33 Score on a Scale Standard Deviation 0.490	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=303)	-0.43 Score on a Scale Standard Deviation 0.540	—
Mean Change From Baseline in HAQ-DI by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=303)	-0.47 Score on a Scale Standard Deviation 0.579	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the HAQ-DI by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1201)	-0.32 Score on a Scale Standard Deviation 0.476	—
Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1201)	-0.47 Score on a Scale Standard Deviation 0.582	—
Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1201)	-0.51 Score on a Scale Standard Deviation 0.612	—
Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2076)	-0.39 Score on a Scale Standard Deviation 0.542	—
Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2076)	-0.51 Score on a Scale Standard Deviation 0.604	—
Mean Change From Baseline in HAQ-DI by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2076)	-0.58 Score on a Scale Standard Deviation 0.653	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the HAQ-DI by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1128)	-0.39 Score on a Scale Standard Deviation 0.545	—
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1128)	-0.54 Score on a Scale Standard Deviation 0.630	—
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1128)	-0.60 Score on a Scale Standard Deviation 0.679	—
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1175)	-0.37 Score on a Scale Standard Deviation 0.533	—
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1175)	-0.48 Score on a Scale Standard Deviation 0.605	—
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1175)	-0.55 Score on a Scale Standard Deviation 0.644	—
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=973)	-0.33 Score on a Scale Standard Deviation 0.470	—
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=973)	-0.46 Score on a Scale Standard Deviation 0.541	—
Mean Change From Baseline in HAQ-DI by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=973)	-0.51 Score on a Scale Standard Deviation 0.580	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the HAQ-DI by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=897)	-0.36 Score on a Scale Standard Deviation 0.547	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=897)	-0.50 Score on a Scale Standard Deviation 0.619	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=897)	-0.57 Score on a Scale Standard Deviation 0.669	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=763)	-0.38 Score on a Scale Standard Deviation 0.532	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=763)	-0.49 Score on a Scale Standard Deviation 0.621	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=763)	-0.56 Score on a Scale Standard Deviation 0.662	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=692)	-0.40 Score on a Scale Standard Deviation 0.531	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=692)	-0.54 Score on a Scale Standard Deviation 0.602	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=692)	-0.58 Score on a Scale Standard Deviation 0.642	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=924)	-0.33 Score on a Scale Standard Deviation 0.470	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=924)	-0.45 Score on a Scale Standard Deviation 0.545	—
Mean Change From Baseline in HAQ-DI by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=924)	-0.52 Score on a Scale Standard Deviation 0.582	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the HAQ-DI by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 to \< =5.1 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=697)	-0.25 Score on a Scale Standard Deviation 0.430	—
Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=697)	-0.33 Score on a Scale Standard Deviation 0.512	—
Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=697)	-0.37 Score on a Scale Standard Deviation 0.525	—
Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2570)	-0.40 Score on a Scale Standard Deviation 0.537	—
Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2570)	-0.54 Score on a Scale Standard Deviation 0.609	—
Mean Change From Baseline in HAQ-DI by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2570)	-0.61 Score on a Scale Standard Deviation 0.658	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the HAQ-DI by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1025)	-0.28 Score on a Scale Standard Deviation 0.486	—
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1025)	-0.41 Score on a Scale Standard Deviation 0.580	—
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1025)	-0.45 Score on a Scale Standard Deviation 0.599	—
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1080)	-0.36 Score on a Scale Standard Deviation 0.496	—
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1080)	-0.48 Score on a Scale Standard Deviation 0.563	—
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1080)	-0.52 Score on a Scale Standard Deviation 0.602	—
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1126)	-0.46 Score on a Scale Standard Deviation 0.559	—
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1126)	-0.60 Score on a Scale Standard Deviation 0.630	—
Mean Change From Baseline in HAQ-DI by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1126)	-0.70 Score on a Scale Standard Deviation 0.686	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the HAQ-DI by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1036)	-0.28 Score on a Scale Standard Deviation 0.475	—
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1036)	-0.41 Score on a Scale Standard Deviation 0.567	—
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1036)	-0.45 Score on a Scale Standard Deviation 0.587	—
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1112)	-0.40 Score on a Scale Standard Deviation 0.527	—
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1112)	-0.52 Score on a Scale Standard Deviation 0.607	—
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1112)	-0.58 Score on a Scale Standard Deviation 0.641	—
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1074)	-0.43 Score on a Scale Standard Deviation 0.535	—
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1074)	-0.55 Score on a Scale Standard Deviation 0.604	—
Mean Change From Baseline in HAQ-DI by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1074)	-0.63 Score on a Scale Standard Deviation 0.666	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1960)	-0.52 Score on a Scale Standard Deviation 0.615	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1960)	-0.59 Score on a Scale Standard Deviation 0.652	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=324)	-0.35 Score on a Scale Standard Deviation 0.462	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=324)	-0.49 Score on a Scale Standard Deviation 0.552	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=324)	-0.52 Score on a Scale Standard Deviation 0.600	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=314)	-0.43 Score on a Scale Standard Deviation 0.505	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=314)	-0.51 Score on a Scale Standard Deviation 0.572	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=314)	-0.57 Score on a Scale Standard Deviation 0.625	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=223)	-0.30 Score on a Scale Standard Deviation 0.480	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=223)	-0.44 Score on a Scale Standard Deviation 0.562	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=454)	-0.37 Score on a Scale Standard Deviation 0.494	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=223)	-0.52 Score on a Scale Standard Deviation 0.628	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=397)	-0.32 Score on a Scale Standard Deviation 0.490	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=454)	-0.48 Score on a Scale Standard Deviation 0.567	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=454)	-0.52 Score on a Scale Standard Deviation 0.622	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=418)	-0.31 Score on a Scale Standard Deviation 0.455	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=418)	-0.40 Score on a Scale Standard Deviation 0.547	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=418)	-0.42 Score on a Scale Standard Deviation 0.572	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=397)	-0.42 Score on a Scale Standard Deviation 0.571	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=397)	-0.45 Score on a Scale Standard Deviation 0.616	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=59)	-0.37 Score on a Scale Standard Deviation 0.517	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=59)	-0.34 Score on a Scale Standard Deviation 0.539	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=59)	-0.42 Score on a Scale Standard Deviation 0.584	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=423)	-0.38 Score on a Scale Standard Deviation 0.513	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=423)	-0.49 Score on a Scale Standard Deviation 0.580	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1960)	-0.38 Score on a Scale Standard Deviation 0.540	—
Mean Change From Baseline in HAQ-DI by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=423)	-0.58 Score on a Scale Standard Deviation 0.642	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the HAQ-DI by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=106)	-0.27 Score on a Scale Standard Deviation 0.406	—
Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=106)	-0.44 Score on a Scale Standard Deviation 0.565	—
Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=106)	-0.47 Score on a Scale Standard Deviation 0.576	—
Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible- Month 2 (n=3171)	-0.37 Score on a Scale Standard Deviation 0.523	—
Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3171)	-0.50 Score on a Scale Standard Deviation 0.597	—
Mean Change From Baseline in HAQ-DI by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 EligAnti-TNF treatment Eligible - Month 6 (n=3171)	-0.56 Score on a Scale Standard Deviation 0.641	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the HAQ-DI by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1211)	-0.46 Score on a Scale Standard Deviation 0.557	—
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1211)	-0.59 Score on a Scale Standard Deviation 0.634	—
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1211)	-0.65 Score on a Scale Standard Deviation 0.691	—
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=1009)	-0.34 Score on a Scale Standard Deviation 0.488	—
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=1009)	-0.48 Score on a Scale Standard Deviation 0.580	—
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=1009)	-0.55 Score on a Scale Standard Deviation 0.610	—
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1053)	-0.29 Score on a Scale Standard Deviation 0.490	—
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1053)	-0.39 Score on a Scale Standard Deviation 0.549	—
Mean Change From Baseline in HAQ-DI by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1053)	-0.44 Score on a Scale Standard Deviation 0.583	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1304)	-0.37 Score on a Scale Standard Deviation 0.515	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1304)	-0.48 Score on a Scale Standard Deviation 0.573	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1304)	-0.55 Score on a Scale Standard Deviation 0.627	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1104)	-0.35 Score on a Scale Standard Deviation 0.511	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1104)	-0.48 Score on a Scale Standard Deviation 0.611	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1104)	-0.54 Score on a Scale Standard Deviation 0.644	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=850)	-0.39 Score on a Scale Standard Deviation 0.535	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=850)	-0.53 Score on a Scale Standard Deviation 0.607	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=850)	-0.59 Score on a Scale Standard Deviation 0.650	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1160)	-0.39 Score on a Scale Standard Deviation 0.533	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1160)	-0.51 Score on a Scale Standard Deviation 0.596	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1160)	-0.60 Score on a Scale Standard Deviation 0.631	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1744)	-0.35 Score on a Scale Standard Deviation 0.511	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1744)	-0.49 Score on a Scale Standard Deviation 0.593	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1744)	-0.53 Score on a Scale Standard Deviation 0.650	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=354)	-0.37 Score on a Scale Standard Deviation 0.512	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=354)	-0.48 Score on a Scale Standard Deviation 0.602	—
Mean Change From Baseline in HAQ-DI by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=354)	-0.54 Score on a Scale Standard Deviation 0.607	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a scores ranging from 0 (best) to 3 (best) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1097)	-0.55 Units on a Scale Standard Deviation 0.664	—
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1055)	-0.39 Units on a Scale Standard Deviation 0.529	—
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1055)	-0.51 Units on a Scale Standard Deviation 0.594	—
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1055)	-0.59 Units on a Scale Standard Deviation 0.625	—
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1060)	-0.35 Units on a Scale Standard Deviation 0.501	—
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1060)	-0.48 Units on a Scale Standard Deviation 0.580	—
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1060)	-0.53 Units on a Scale Standard Deviation 0.627	—
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1097)	-0.36 Units on a Scale Standard Deviation 0.529	—
Mean Change From Baseline in HAQ-DI by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1097)	-0.50 Units on a Scale Standard Deviation 0.609	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The HAQ-DI assesses 8 categories of daily activity including dressing, arising, eating, walking, hygiene, reach, grip, and common activities with a score 0 (best) to 3 (worst) with 0=able to do, 1=with some difficulty, 2=with much difficulty, and 3=unable to do for a combined total score of 0 (best) to 32 (worst). The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=40)	-0.36 Units on a Scale Standard Deviation 0.563	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=40)	-0.49 Units on a Scale Standard Deviation 0.536	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=40)	-0.54 Units on a Scale Standard Deviation 0.593	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=325)	-0.29 Units on a Scale Standard Deviation 0.482	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=325)	-0.43 Units on a Scale Standard Deviation 0.529	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=325)	-0.49 Units on a Scale Standard Deviation 0.575	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1930)	-0.38 Units on a Scale Standard Deviation 0.526	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1930)	-0.51 Units on a Scale Standard Deviation 0.610	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1930)	-0.57 Units on a Scale Standard Deviation 0.642	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=966)	-0.38 Units on a Scale Standard Deviation 0.515	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=966)	-0.49 Units on a Scale Standard Deviation 0.587	—
Mean Change From Baseline in HAQ-DI by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=966)	-0.54 Units on a Scale Standard Deviation 0.653	—

SECONDARY outcome

Timeframe: Month 2, Month 4, Month 6

Population: The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.

The number of participants that achieved minimal or absence of functional impairment as assessed by the HAQ at study Month 2, Month 4, and Month 6 was calculated. Minimal or absence of functional impairment was defined as a HAQ score of \<=0.5. The HAQ evaluates participants on a scale of 0 to 3, with 0=with no difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Number of Participants Who Achieved Minimal or Absence of Functional Impairment Study Month 4	1087 Participants	—
Number of Participants Who Achieved Minimal or Absence of Functional Impairment Study Month 6	1226 Participants	—
Number of Participants Who Achieved Minimal or Absence of Functional Impairment Study Month 2	865 Participants	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

Concomitant MTX dose was defined as low \< 10mg/wk, medium \>= 10 to \< 15 mg/week, and and high \>=15 mg/week. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 2 (n=142)	0.20 Score on a Scale Standard Deviation 0.331	—
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 4 (n=142)	0.25 Score on a Scale Standard Deviation 0.318	—
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Low MTX Dose - Month 6 (n=142)	0.26 Score on a Scale Standard Deviation 0.312	—
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 2 (n=526)	0.20 Score on a Scale Standard Deviation 0.325	—
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 4 (n=526)	0.24 Score on a Scale Standard Deviation 0.338	—
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 Medium MTX Dose - Month 6 (n=526)	0.27 Score on a Scale Standard Deviation 0.332	—
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 2 (n=1985)	0.20 Score on a Scale Standard Deviation 0.311	—
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 4 (n=1985)	0.23 Score on a Scale Standard Deviation 0.336	—
Mean Change From Baseline in the EuroQOL (EQ-5D) Quality-of-Life Questionnaire by Concomitant MTX Dose at Month 2, Month 4, and Month 6 High MTX Dose - Month 6 (n=1985)	0.26 Score on a Scale Standard Deviation 0.346	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. DMARD Combination 1=MTX + hydrochloroquine, chloroquine, chloroquine phosphate; Combination 2=MTX + leflunomide; Combination 3=MTX +sulfasalazine; Combination 4=MTX + hydrochloroquine, chloroquine, chloroquine phosphate+sulfasalazine; Combination 5=leflunomide.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 2 (n=1672)	0.21 Score on a Scale Standard Deviation 0.313	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 4 (n=1672)	0.24 Score on a Scale Standard Deviation 0.336	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 1 - Month 6 (n=1672)	0.26 Score on a Scale Standard Deviation 0.341	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 2 (n=432)	0.19 Score on a Scale Standard Deviation 0.316	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 4 (n=432)	0.23 Score on a Scale Standard Deviation 0.337	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 2 - Month 6 (n=432)	0.27 Score on a Scale Standard Deviation 0.346	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 2 (n=216)	0.16 Score on a Scale Standard Deviation 0.343	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 4 (n=216)	0.18 Score on a Scale Standard Deviation 0.355	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 3 - Month 6 (n=216)	0.21 Score on a Scale Standard Deviation 0.325	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 2 (n=150)	0.25 Score on a Scale Standard Deviation 0.307	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 -Month 4 (n=150)	0.24 Score on a Scale Standard Deviation 0.316	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 4 - Month 6 (n=150)	0.26 Score on a Scale Standard Deviation 0.349	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 2 (n=105)	0.22 Score on a Scale Standard Deviation 0.273	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 4 (n=105)	0.28 Score on a Scale Standard Deviation 0.302	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 5 - Month 6 (n=105)	0.29 Score on a Scale Standard Deviation 0.374	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 2 (n=303)	0.17 Score on a Scale Standard Deviation 0.284	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 4 (n=303)	0.21 Score on a Scale Standard Deviation 0.306	—
Mean Change From Baseline in EQ-5D by Concomitant DMARD Background Treatment at Month 2, Month 4, and Month 6 DMARD Combination 6 - Month 6 (n=303)	0.19 Score on a Scale Standard Deviation .341	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the EQ-5D by participant concomitant corticosteroid use was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 2 (n=1199)	0.17 Score on a Scale Standard Deviation 0.291	—
Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 4 (n=1199)	0.21 Score on a Scale Standard Deviation 0.306	—
Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Did Not Receive Corticosteroids - Month 6 (n=1199)	0.22 Score on a Scale Standard Deviation 0.329	—
Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 2 (n=2069)	0.21 Score on a Scale Standard Deviation 0.322	—
Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 4 (n=2069)	0.24 Score on a Scale Standard Deviation 0.343	—
Mean Change From Baseline in EQ-5D by Concomitant Corticosteroid Treatment at Month 2, Month 4, and Month 6 Received Corticosteroids - Month 6 (n=2069)	0.27 Score on a Scale Standard Deviation 0.348	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the EQ-5D by the number of participant DMARD failures was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 2 (n=1124)	0.21 Score on a Scale Standard Deviation 0.324	—
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 4 (n=1124)	0.24 Score on a Scale Standard Deviation 0.338	—
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 1 DMARD - Month 6 (n=1124)	0.27 Score on a Scale Standard Deviation 0.347	—
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 2 (n=1173)	0.19 Score on a Scale Standard Deviation 0.312	—
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 4 (n=1173)	0.22 Score on a Scale Standard Deviation 0.329	—
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed 2 DMARDs - Month 6 (n=1173)	0.24 Score on a Scale Standard Deviation 0.346	—
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 2 (n=970)	0.19 Score on a Scale Standard Deviation 0.298	—
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 4 (n=970)	0.22 Score on a Scale Standard Deviation 0.323	—
Mean Change From Baseline in EQ-5D by the Number of DMARD Failures at Month 2, Month 4, and Month 6 Failed >=3 DMARDs - Month 6 (n=970)	0.24 Score on a Scale Standard Deviation 0.331	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the EQ-5D by the participant duration of disease was calculated at study Month 2, Month 4, and Month 6. The duration of disease is defined as the time since the diagnosis of rheumatoid arthritis. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 4 (n=760)	0.23 Score on a Scale Standard Deviation 0.319	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 6 (n=760)	0.24 Score on a Scale Standard Deviation 0.339	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 2 (n=691)	0.22 Score on a Scale Standard Deviation 0.315	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 4 (n=691)	0.24 Score on a Scale Standard Deviation 0.341	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration 5 to 10 years - Month 6 (n=691)	0.26 Score on a Scale Standard Deviation 0.357	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 2 (n=923)	0.19 Score on a Scale Standard Deviation 0.307	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 4 (n=923)	0.23 Score on a Scale Standard Deviation 0.323	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration > 10 years - Month 6 (n=923)	0.25 Score on a Scale Standard Deviation 0.334	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 2 (n=893)	0.18 Score on a Scale Standard Deviation 0.315	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 4 (n=893)	0.21 Score on a Scale Standard Deviation 0.339	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration < 2 years - Month 6 (n=893)	0.24 Score on a Scale Standard Deviation 0.342	—
Mean Change From Baseline in EQ-5D by Duration of Disease at Month 2, Month 4, and Month 6 Duration 2 to <5 years - Month 2 (n=760)	0.21 Score on a Scale Standard Deviation 0.311	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the EQ-5D by the participant baseline level of disease activity was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. DAS28-ESR \> 5.1 = high disease activity, DAS28-ESR \< 3.2 to \< =5.1 = low disease activity, and DAS28-ESR \<2.6 = remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 2 (n=695)	0.10 Score on a Scale Standard Deviation 0.232	—
Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 4 (n=695)	0.12 Score on a Scale Standard Deviation 0.253	—
Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 3.2 to <=5.1 - Month 6 (n=695)	0.13 Score on a Scale Standard Deviation 0.267	—
Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 2 (n=2563)	0.22 Score on a Scale Standard Deviation 0.325	—
Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 4 (n=2563)	0.26 Score on a Scale Standard Deviation 0.343	—
Mean Change From Baseline in EQ-5D by Baseline Level of Disease Activity at Month 2, Month 4, and Month 6 DAS28 > 5.1 - Month 6 (n=2563)	0.28 Score on a Scale Standard Deviation 0.353	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the EQ-5D by the participant baseline RF level was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 2 (n=1020)	0.16 Score on a Scale Standard Deviation 0.296	—
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 4 (n=1020)	0.19 Score on a Scale Standard Deviation 0.322	—
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF <=22 IU/mL - Month 6 (n=1020)	0.21 Score on a Scale Standard Deviation 0.314	—
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 2 (n=1079)	0.19 Score on a Scale Standard Deviation 0.305	—
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 4 (n=1079)	0.22 Score on a Scale Standard Deviation 0.324	—
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF >22 to <=146 IU/mL - Month 6 (n=1079)	0.23 Score on a Scale Standard Deviation 0.339	—
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 2 (n=1123)	0.25 Score on a Scale Standard Deviation 0.328	—
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 4 (n=1123)	0.27 Score on a Scale Standard Deviation 0.338	—
Mean Change From Baseline in EQ-5D by Baseline RF Level at Month 2, Month 4, and Month 6 RF >146 IU/mL - Month 6 (n=1123)	0.30 Score on a Scale Standard Deviation 0.365	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the EQ-5D by the participant baseline serum level of anti-CCP was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 2 (n=1033)	0.15 Score on a Scale Standard Deviation 0.297	—
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 4 (n=1033)	0.19 Score on a Scale Standard Deviation 0.324	—
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP <=40 U/mL - Month 6 (n=1033)	0.21 Score on a Scale Standard Deviation 0.319	—
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 2 (n=1109)	0.21 Score on a Scale Standard Deviation 0.313	—
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 4 (n=1109)	0.24 Score on a Scale Standard Deviation 0.328	—
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >40 to <=380 U/mL - Month 6 (n=1109)	0.25 Score on a Scale Standard Deviation 0.343	—
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 2 (n=1071)	0.23 Score on a Scale Standard Deviation 0.321	—
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 4 (n=1071)	0.25 Score on a Scale Standard Deviation 0.336	—
Mean Change From Baseline in EQ-5D by Baseline Anti-CCP Level at Month 2, Month 4, and Month 6 Anti-CCP >380 U/mL - Month 6 (n=1071)	0.28 Score on a Scale Standard Deviation 0.28	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Pack years smoked is defined as the total number of packs smoked per day multiplied by the number of years the participant smoked.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 2 (n=1957)	0.21 Score on a Scale Standard Deviation 0.319	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 4 (n=1957)	0.24 Score on a Scale Standard Deviation 0.334	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Non-Smoker - Month 6 (n=1957)	0.27 Score on a Scale Standard Deviation 0.339	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 2 (n=322)	0.18 Score on a Scale Standard Deviation 0.300	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 4 (n=322)	0.20 Score on a Scale Standard Deviation 0.304	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Smoking history >=20 years - Month 6 (n=322)	0.21 Score on a Scale Standard Deviation 0.324	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 2 (n=312)	0.19 Score on a Scale Standard Deviation 0.315	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 4 (n=312)	0.22 Score on a Scale Standard Deviation 0.334	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Smoking history <20 years - Month 6 (n=312)	0.24 Score on a Scale Standard Deviation 0.351	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 2 (n=223)	0.16 Score on a Scale Standard Deviation 0.301	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 packs/day - Month 4 (n=223)	0.20 Score on a Scale Standard Deviation 0.338	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes <0.5 pack/day - Month 6 (n=223)	0.24 Score on a Scale Standard Deviation 0.344	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 2 (n=395)	0.20 Score on a Scale Standard Deviation 0.296	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 4 (n=395)	0.20 Score on a Scale Standard Deviation 0.327	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes 0.5-1 pack/day - Month 6 (n=395)	0.21 Score on a Scale Standard Deviation 0.363	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 2 (n=59)	0.14 Score on a Scale Standard Deviation 0.269	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 4 (n=59)	0.15 Score on a Scale Standard Deviation 0.292	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Currently smokes >1 packs/day - Month 6 (n=59)	0.19 Score on a Scale Standard Deviation 0.325	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 2 (n=421)	0.21 Score on a Scale Standard Deviation 0.314	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 4 (n=421)	0.22 Score on a Scale Standard Deviation 0.333	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years <7.5 - Month 6 (n=421)	0.26 Score on a Scale Standard Deviation 0.357	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 2 (n=453)	0.17 Score on a Scale Standard Deviation 0.284	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 4 (n=453)	0.20 Score on a Scale Standard Deviation 0.310	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years 7.5 to 20.5 - Month 6 (n=453)	0.335 Score on a Scale Standard Deviation 0.19	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 2 (n=415)	0.17 Score on a Scale Standard Deviation 0.301	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 4 (n=415)	0.19 Score on a Scale Standard Deviation 0.325	—
Mean Change From Baseline in EQ-5D by Smoking Status at Month 2, Month 4, and Month 6 Pack years >20.5 - Month 6 (n=415)	0.19 Score on a Scale Standard Deviation 0.342	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the EQ-5D by the participant eligibility for anti-TNF treatment was calculated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 4 (n=3162)	0.23 Score on a Scale Standard Deviation 0.331	—
Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 2 (n=106)	0.15 Score on a Scale Standard Deviation 0.298	—
Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 4 (n=106)	0.18 Score on a Scale Standard Deviation 0.305	—
Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Ineligible - Month 6 (n=106)	0.19 Score on a Scale Standard Deviation 0.305	—
Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 2 (n=3162)	0.20 Score on a Scale Standard Deviation 0.312	—
Mean Change From Baseline in EQ-5D by Eligibility for Anti-TNF Treatment at Month 2, Month 4, and Month 6 Anti-TNF treatment Eligible - Month 6 (n=3162)	0.25 Score on a Scale Standard Deviation 0.343	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The mean change from baseline in the EQ-5D by the participant baseline expectation of treatment outcome was evaluated at study Month 2, Month 4, and Month 6. The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The participant expectation scale was evaluated by questionnaire for a categorical score of 1 (best) to 5 (worst).

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 2 (n=1208)	0.22 Score on a Scale Standard Deviation 0.323	—
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 4 (n=1208)	0.26 Score on a Scale Standard Deviation 0.337	—
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 <=1.5 - Month 6 (n=1208)	0.28 Score on a Scale Standard Deviation 0.349	—
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 2 (n=1006)	0.20 Score on a Scale Standard Deviation 0.304	—
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 4 (n=1006)	0.23 Score on a Scale Standard Deviation 0.319	—
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >1.5 to 1.86 - Month 6 (n=1006)	0.25 Score on a Scale Standard Deviation 0.331	—
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 2 (n=1050)	0.17 Score on a Scale Standard Deviation 0.304	—
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 4 (n=1050)	0.19 Score on a Scale Standard Deviation 0.329	—
Mean Change From Baseline in EQ-5D by Participant Baseline Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 >=1.86 - Month 6 (n=1050)	0.21 Score on a Scale Standard Deviation 0.341	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Physician experience is defined as the number of years the treating physician has experience managing patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 2 (n=1300)	0.20 Score on a Scale Standard Deviation 0.311	—
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 4 (n=1300)	0.23 Score on a Scale Standard Deviation 0.335	—
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 <=10 years - Month 6 (n=1300)	0.25 Score on a Scale Standard Deviation 0.352	—
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 2 (n=1103)	0.18 Score on a Scale Standard Deviation 0.316	—
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 4 (n=1103)	0.22 Score on a Scale Standard Deviation 0.331	—
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 >10 to 20 years - Month 6 (n=1103)	0.24 Score on a Scale Standard Deviation 0.340	—
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 2 (n=847)	0.21 Score on a Scale Standard Deviation 0.309	—
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 4 (n=847)	0.25 Score on a Scale Standard Deviation 0.322	—
Mean Change From Baseline in EQ-5D by Physician Experience Level at Month 2, Month 4, and Month 6 >20 years - Month 6 (n=847)	0.26 Score on a Scale Standard Deviation 0.330	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. Physician experience is defined as the number of years the treating physician has experience managing rheumatoid arthritis with biologics.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 2 (n=1154)	0.21 Score on a Scale Standard Deviation 0.319	—
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 4 (n=1154)	0.24 Score on a Scale Standard Deviation 0.347	—
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 0 to 6 years - Month 6 (n=1154)	0.26 Score on a Scale Standard Deviation 0.356	—
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 2 (n=1743)	0.19 Score on a Scale Standard Deviation 0.310	—
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 4 (n=1743)	0.23 Score on a Scale Standard Deviation 0.324	—
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 6 to 10 years - Month 6 (n=1743)	0.24 Score on a Scale Standard Deviation 0.338	—
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 2 (n=353)	0.18 Score on a Scale Standard Deviation 0.300	—
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 4 (n=353)	0.21 Score on a Scale Standard Deviation 0.309	—
Mean Change From Baseline in EQ-5D by Physician Experience Level With Biologics at Month 2, Month 4, and Month 6 >10 years - Month 6 (n=353)	0.24 Score on a Scale Standard Deviation 0.318	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant is asked to indicate their health state by ticking the box against the most appropriate statement in each of the 5 dimensions. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The number of patients treated with biologics is defined as the number of patients with rheumatoid arthritis treated by the physician in the last month with biologic agents.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 6 (n=1093)	0.25 Units on a Scale Standard Deviation 0.350	—
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 2 (n=1052)	0.21 Units on a Scale Standard Deviation 0.307	—
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 4 (n=1052)	0.24 Units on a Scale Standard Deviation 0.326	—
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 1-17 patients in prior month - Month 6 (n=1052)	0.26 Units on a Scale Standard Deviation 0.339	—
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 2 (n=1059)	0.18 Units on a Scale Standard Deviation 0.312	—
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 4 (n=1059)	0.21 Units on a Scale Standard Deviation 0.327	—
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 18-34 patients in prior month - Month 6 (n=1059)	0.24 Units on a Scale Standard Deviation 0.338	—
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 2 (n=1093)	0.20 Units on a Scale Standard Deviation 0.319	—
Mean Change From Baseline in EQ-5D by the Number of Patients Treated by the Physician With Biologics at Month 2, Month 4, and Month 6 >=35 patients in prior month - Month 4 (n=1093)	0.24 Units on a Scale Standard Deviation 0.340	—

SECONDARY outcome

Timeframe: Baseline, Month 2, Month 4, Month 6

The EQ-5D assesses the 5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant indicates their health state by ticking the box against the most appropriate statement. The digits (1 \[best\] to 3 \[worst\]; with 0= no problems, 1 = some problems, 2 = some problems, and 3= severe problems) for the 5 dimensions can be combined in a 5-digit number describing the participant's health state. The numerals 1 to 3 have no arithmetic properties and should not be used as a cardinal score. The physician's expectation of treatment outcome was assessed at the start of Month 4, when physicians were asked to rate their expectations of treatment outcome as: high disease activity, moderate disease activity, low disease activity, or remission.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 2 (n=38)	0.24 Units on a Scale Standard Deviation 0.315	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 4 (n=38)	0.20 Units on a Scale Standard Deviation 0.355	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 High disease activity - Month 6 (n=38)	0.20 Units on a Scale Standard Deviation 0.352	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 2 (n=325)	0.18 Units on a Scale Standard Deviation 0.298	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 4 (n=325)	0.23 Units on a Scale Standard Deviation 0.320	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Moderate disease activity - Month 6 (n=325)	0.25 Units on a Scale Standard Deviation 0.320	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 2 (n=1926)	0.20 Units on a Scale Standard Deviation 0.323	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 4 (n=1926)	0.23 Units on a Scale Standard Deviation 0.335	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Low disease activity - Month 6 (n=1926)	0.25 Units on a Scale Standard Deviation 0.349	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 2 (n=964)	0.19 Units on a Scale Standard Deviation 0.295	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 4 (n=964)	0.22 Units on a Scale Standard Deviation 0.323	—
Mean Change From Baseline in EQ-5D by the the Physician Expectation of Treatment Outcome at Month 2, Month 4, and Month 6 Remission - Month 6 (n=964)	0.23 Units on a Scale Standard Deviation 0.335	—

SECONDARY outcome

Timeframe: Month 2, Month 4, Month 6

Population: The efficacy evaluable population comprised all participants with a baseline DAS28-ESR and at least one post-baseline measurement of DAS28-ESR.

The number of participants achieving PASS was evaluated at study Month 2, Month 4, and Month 6 was calculated. PASS is participant self-evaluation tool that uses a VAS 0mm (best) - 100mm (worst), with a score \<=31 representing an acceptable PASS.

Outcome measures

Outcome measures
Measure	GLM50-SC n=3280 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Number of Participants With a Participant Acceptable Symptom State (PASS) at Month 4, Month 6, and Month 8 Study Month 2	1578 Participants	—
Number of Participants With a Participant Acceptable Symptom State (PASS) at Month 4, Month 6, and Month 8 Study Month 4	1889 Participants	—
Number of Participants With a Participant Acceptable Symptom State (PASS) at Month 4, Month 6, and Month 8 Study Month 6	2164 Participants	—

SECONDARY outcome

Timeframe: End of Month 6, End of Month 12

Population: 8 participants (3 poor quality data, 4 without a post-baseline DAS28-ESR, and 1 did not take Part 2 medication) and 7 participants (5 poor data quality, 1 without a DAS28-ESR at baseline, 1 without post-baseline DAS28-ESR) were excluded from the efficacy evaluable population for the IV-GLM 2mg/kg + SC GLM 50 mg and SC-GLM50 arms, respectively.

The DAS28-ESR is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR, and participant assessment of disease activity measure on a visual analogue scale. The DAS28-ESR has numeric thresholds that define high disease activity (\> 5.1), low disease activity (\< 3.2) and remission (\< 2.6). Minimum score=0 (best) to maximum score=10 (worst). The DAS28-ESR area under the curve can be calculated from the DAS28-ESR score versus time curve to provide an assessment of changes in disease activity over time. The area under the DAS28-ESR score versus time curve was computed using the trapezoidal rule and using raw DAS28-ESR score values at Part-2 Baseline, end of Month 12, and at least 2 intermediate time points. The DAS28-ESR area under the curve was then averaged over the total duration (months) and expressed as units on a scale.

Outcome measures

Outcome measures
Measure	GLM50-SC n=242 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 n=248 Participants Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Mean Area Under the DAS28-ESR Curve From Study Month 6 to Month 12	3.67 Units on a Scale Standard Deviation 0.992	3.67 Units on a Scale Standard Deviation 0.924

SECONDARY outcome

Timeframe: Start of Month 8, Start of Month 9, Start of Month 10, Start of Month 11, End of Month 12

Remission was defined as achievement of a DAS28-ESR \< 2.6.

Outcome measures

Outcome measures
Measure	GLM50-SC n=242 Participants Participants received subcutaneous golimumab 50 mg once monthly.	SC-GLM50 n=248 Participants Subcutaneous golimumab 50 mg administered once monthly for for 6 months (study Months 6-12).
Percentage of Participants Achieving Remission Start of Month 8	19.8 Percentage of Participants Interval 15.3 to 25.4	13.7 Percentage of Participants Interval 10.0 to 18.7
Percentage of Participants Achieving Remission Start of Month 9	28.2 Percentage of Participants Interval 23.0 to 34.4	20.1 Percentage of Participants Interval 15.7 to
Percentage of Participants Achieving Remission Start of Month 10	34.2 Percentage of Participants Interval 28.6 to 40.6	29.5 Percentage of Participants Interval to 35.6
Percentage of Participants Achieving Remission Start of Month 11	40.3 Percentage of Participants Interval 34.3 to 46.8	39.3 Percentage of Participants Interval 33.5 to 45.7
Percentage of Participants Achieving Remission End of Month 12	44.3 Percentage of Participants Interval 38.2 to 50.9	45.1 Percentage of Participants Interval 39.1 to 51.5

Adverse Events

Golimumab 50 mg Subcutaneous (GLM50-SC)

Serious events: 203 serious events

Other events: 0 other events

Deaths: 0 deaths

Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg

Serious events: 17 serious events

Other events: 28 other events

Deaths: 0 deaths

SC-GLM50

Serious events: 7 serious events

Other events: 24 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Golimumab 50 mg Subcutaneous (GLM50-SC) n=3357 participants at risk Participants received GLM50-SC once monthly for a period of 6 months.	Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg n=245 participants at risk Participants received IV-GLM at a dose of 2 mg/kg at the start of Month 7, start of Month 8, and start of Month 10 if remission was not achieved at any of these IV administration visits. If remission was achieved, participants were switched subcutaneous golimumab at a dose of 50 mg once monthly.	SC-GLM50 n=255 participants at risk Participants received subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months in Part 2 of the study.
Infections and infestations Pneumonia	0.27% 9/3357 • Number of events 10	0.82% 2/245 • Number of events 2	0.39% 1/255 • Number of events 1
Infections and infestations Arthritis bacterial	0.15% 5/3357 • Number of events 5	0.00% 0/245	0.00% 0/255
Infections and infestations Sepsis	0.15% 5/3357 • Number of events 5	0.41% 1/245 • Number of events 1	0.00% 0/255
Infections and infestations Tuberculosis	0.12% 4/3357 • Number of events 5	0.00% 0/245	0.00% 0/255
Infections and infestations Respiratory tract infection	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Infections and infestations Urinary Tract Infection	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Infections and infestations Cellulitis	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Infections and infestations Gastroenteritis	0.06% 2/3357 • Number of events 2	0.41% 1/245 • Number of events 1	0.00% 0/255
Infections and infestations Peritonsillar abcess	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Infections and infestations Rotavirus infection	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Infections and infestations Viral infection	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Infections and infestations Abcess oral	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Bacterial pyelonephritis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Beta haemolytic streptococcal infection	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Bronchitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Erysipelas	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Groin abcess	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Helicobacter gastritis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Herpes zoster	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.39% 1/255 • Number of events 1
Infections and infestations Herpes zoster oticus	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Infected skin ulcer	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Listeria sepsis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Lower respiratory tract infection	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Ludwig angina	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Lung infection	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Lymph node tuberculosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Paronychia	0.00% 0/3357	0.41% 1/245 • Number of events 1	0.00% 0/255
Infections and infestations Pyelonephritis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.39% 1/255 • Number of events 1
Infections and infestations Oral candidiasis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Osteomyelitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Otitis media acute	0.03% 1/3357 • Number of events 1	0.41% 1/245 • Number of events 1	0.00% 0/255
Infections and infestations Pharyngitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Pneumocystis jiroveci pneumonia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Rash pustular	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Salmonellosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Septic shock	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Sinusitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Syphillis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Tonsillitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Infections and infestations Tracheitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Fibromyalgia	0.00% 0/3357	0.41% 1/245 • Number of events 1	0.00% 0/255
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	0.27% 9/3357 • Number of events 9	0.41% 1/245 • Number of events 1	0.00% 0/255
Musculoskeletal and connective tissue disorders Back pain	0.12% 4/3357 • Number of events 4	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Arthralgia	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Osteoarthritis	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Arthritis	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Arthropathy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Intervertebral disc disorder	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Lumbar spine stenosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Meniscal degeneration	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Osteonecrosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Polychondritis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Synovial cyst	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/3357	0.41% 1/245 • Number of events 1	0.00% 0/255
Injury, poisoning and procedural complications Overdose	0.15% 5/3357 • Number of events 5	0.82% 2/245 • Number of events 2	0.39% 1/255 • Number of events 1
Injury, poisoning and procedural complications Alcohol poisoning	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Fall	0.06% 2/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Femur fracture	0.06% 2/3357 • Number of events 2	0.41% 1/245 • Number of events 1	0.00% 0/255
Injury, poisoning and procedural complications Joint injury	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Musculoskeletal and connective tissue disorders Ankle fracture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Face injury	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Femoral neck fracture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Forearm fracture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Hip fracture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Joint dislocation	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Multiple fractures	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Rib fracture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Spinal compression fracture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Spinal fracture	0.03% 1/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Synovial rupture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Thermal burn	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Tibia fracture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Upper limb fracture	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Injury, poisoning and procedural complications Wound	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.12% 4/3357 • Number of events 4	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cervix carcinoma	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Diffuse large B-cell carcinoma	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.03% 1/3357 • Number of events 1	0.41% 1/245 • Number of events 1	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic gastric cancer	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Multiple myeloma	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Vulval cancer	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer in situ	0.00% 0/3357	0.00% 0/245	0.39% 1/255 • Number of events 1
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cervix carcinoma stage 0	0.00% 0/3357	0.00% 0/245	0.39% 1/255 • Number of events 1
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid cancer	0.00% 0/3357	0.00% 0/245	0.39% 1/255 • Number of events 1
Gastrointestinal disorders Abdominal pain	0.09% 3/3357 • Number of events 4	0.41% 1/245 • Number of events 1	0.00% 0/255
Gastrointestinal disorders Gastritis	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Gastrointestinal haemorrhage	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Gastrooesophageal reflux disease	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Appendix disorder	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Diarrhoea	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Dyspepsia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Enterocolitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Gastritis atrophic	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Gastritis erosive	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Lumbar hernia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Mouth ulceration	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Oesophageal varicies hemorrhage	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Oesophagitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Rectal hemorrhage	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Small intestine obstruction	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Vomiting	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Gastrointestinal disorders Colitis ulcerative	0.00% 0/3357	0.41% 1/245 • Number of events 1	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.12% 4/3357 • Number of events 4	0.41% 1/245 • Number of events 1	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.09% 3/3357 • Number of events 4	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Bronchopneumopathy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Bronchospasm	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Lung cyst	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Pleurisy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/3357	0.41% 1/245 • Number of events 2	0.00% 0/255
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/3357	0.41% 1/245 • Number of events 1	0.00% 0/255
Cardiac disorders Atrial fibriliation	0.09% 3/3357 • Number of events 4	0.41% 1/245 • Number of events 1	0.00% 0/255
Cardiac disorders Acute myocardial infarction	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Cardiac disorders Angina pectoris	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Cardiac disorders Myocardial infarction	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Cardiac disorders Angina unstable	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Cardiac disorders Arrhythmia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Cardiac disorders Cardiac failure congestive	0.03% 1/3357 • Number of events 1	0.41% 1/245 • Number of events 1	0.00% 0/255
Cardiac disorders Cardiopulmonary failure	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Cardiac disorders Palpitations	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Cardiac disorders Tachyarrhythmia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Nervous system disorders Cerebral infarction	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Nervous system disorders Sciatica	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Nervous system disorders Carpal tunnel syndrome	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Nervous system disorders Cerebrovascular accident	0.03% 1/3357 • Number of events 1	0.41% 1/245 • Number of events 1	0.00% 0/255
Nervous system disorders Convulsion	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Nervous system disorders Epilepsy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Nervous system disorders Hemiparesis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Nervous system disorders Polyneuropathy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Nervous system disorders Syncope	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Nervous system disorders Transient ischaemic attack	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Nervous system disorders Vertebrobasilar insufficiency	0.00% 0/3357	0.41% 1/245 • Number of events 1	0.00% 0/255
General disorders Pyrexia	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
General disorders Malaise	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
General disorders Calcinosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
General disorders Chest pain	0.03% 1/3357 • Number of events 1	0.41% 1/245 • Number of events 1	0.00% 0/255
General disorders General physical health deterioration	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
General disorders Impaired healing	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
General disorders Multi-organ failure	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
General disorders Oedema peripheral	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
General disorders Pain	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Vascular disorders Deep vein thrombosis	0.12% 4/3357 • Number of events 4	0.00% 0/245	0.00% 0/255
Vascular disorders Circulatory collapse	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Vascular disorders Arteriosclerosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Vascular disorders Hypertension	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Vascular disorders Hypertensive crisis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Vascular disorders Thrombophlebitis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Renal and urinary disorders Renal failure acute	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Renal and urinary disorders Calculus bladder	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Renal and urinary disorders Nephrolithiases	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Renal and urinary disorders Renal amyloidosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Renal and urinary disorders Renal failure	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Metabolism and nutrition disorders Diabetes mellitus	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Metabolism and nutrition disorders Dehydration	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Metabolism and nutrition disorders Hypoglycaemia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Metabolism and nutrition disorders Hypokalaemia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Metabolism and nutrition disorders Hyponatraemia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Blood and lymphatic system disorders Leukopenia	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Blood and lymphatic system disorders Lymphadenopathy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Blood and lymphatic system disorders Thrombocytopenia	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Hepatobiliary disorders Cholecystitis	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Hepatobiliary disorders Liver disorder	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Hepatobiliary disorders Cholestasis	0.00% 0/3357	0.41% 1/245 • Number of events 1	0.00% 0/255
Skin and subcutaneous tissue disorders Angioedema	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Skin and subcutaneous tissue disorders Dermatitis allergic	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Skin and subcutaneous tissue disorders Dermatitis exfoliative	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Skin and subcutaneous tissue disorders Dermatitis psoriasiform	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Skin and subcutaneous tissue disorders Erythema	0.00% 0/3357	0.00% 0/245	0.39% 1/255 • Number of events 1
Surgical and medical procedures Arterial bypass operation	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Surgical and medical procedures Arthrodesis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Surgical and medical procedures Hysterectomy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Surgical and medical procedures Lymphadenectomy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Immune system disorders Drug hypersensitivity	0.09% 3/3357 • Number of events 3	0.00% 0/245	0.00% 0/255
Investigations Blood pressure increased	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Investigations Body temperature increased	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Investigations Transaminases increased	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Investigations Weight increased	0.00% 0/3357	0.00% 0/245	0.39% 1/255 • Number of events 1
Psychiatric disorders Depression	0.06% 2/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Psychiatric disorders Panic attack	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Reproductive system and breast disorders Endometrial hypertrophy	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Reproductive system and breast disorders Endometriosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Reproductive system and breast disorders Fibrocystic breast disease	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Reproductive system and breast disorders Ovarian cyst	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Eye disorders Cataract	0.03% 1/3357 • Number of events 2	0.00% 0/245	0.00% 0/255
Eye disorders Open angle glaucoma	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Congenital, familial and genetic disorders Pyloric stenosis	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Ear and labyrinth disorders Conductive deafness	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255
Pregnancy, puerperium and perinatal conditions Abortion spontaneous	0.03% 1/3357 • Number of events 1	0.00% 0/245	0.00% 0/255

Other adverse events

Other adverse events
Measure	Golimumab 50 mg Subcutaneous (GLM50-SC) n=3357 participants at risk Participants received GLM50-SC once monthly for a period of 6 months.	Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg n=245 participants at risk Participants received IV-GLM at a dose of 2 mg/kg at the start of Month 7, start of Month 8, and start of Month 10 if remission was not achieved at any of these IV administration visits. If remission was achieved, participants were switched subcutaneous golimumab at a dose of 50 mg once monthly.	SC-GLM50 n=255 participants at risk Participants received subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months in Part 2 of the study.
Infections and infestations Nasopharyngitis	0.00% 0/3357	5.3% 13/245 • Number of events 15	7.1% 18/255 • Number of events 19
Infections and infestations Upper respiratory tract infection	0.00% 0/3357	6.1% 15/245 • Number of events 17	2.4% 6/255 • Number of events 9

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Investigator is granted the right to use the results of all work under this study including but not limited to, the results of tests and any raw data and statistical data generated for investigator's own teaching, research, and publication purposes only. Investigator/Institution agrees, on behalf of itself and its employees, officers, trustees, and agents, not to cause said results to be knowingly used for any commercial purpose whatsoever except as authorized by the sponsor in writing.
Publication restrictions are in place

Restriction type: OTHER